NZ724880B2 - Aberrant cell-restricted immunoglobulins provided with a toxic moiety - Google Patents
Aberrant cell-restricted immunoglobulins provided with a toxic moiety Download PDFInfo
- Publication number
- NZ724880B2 NZ724880B2 NZ724880A NZ72488013A NZ724880B2 NZ 724880 B2 NZ724880 B2 NZ 724880B2 NZ 724880 A NZ724880 A NZ 724880A NZ 72488013 A NZ72488013 A NZ 72488013A NZ 724880 B2 NZ724880 B2 NZ 724880B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- hla
- immunoglobulin
- seq
- toxic moiety
- cells
- Prior art date
Links
- 102000018358 Immunoglobulins Human genes 0.000 title claims abstract description 144
- 108060003951 Immunoglobulins Proteins 0.000 title claims abstract description 144
- 230000002588 toxic Effects 0.000 title claims abstract description 117
- 231100000331 toxic Toxicity 0.000 title claims abstract description 116
- 230000001594 aberrant Effects 0.000 title claims abstract description 77
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 title description 44
- 108090001123 antibodies Proteins 0.000 claims abstract description 136
- 102000004965 antibodies Human genes 0.000 claims abstract description 136
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims abstract description 33
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 230000035693 Fab Effects 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 3
- 210000004027 cells Anatomy 0.000 description 217
- 230000027455 binding Effects 0.000 description 176
- 210000001744 T-Lymphocytes Anatomy 0.000 description 79
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 51
- 108020004707 nucleic acids Proteins 0.000 description 41
- 150000007523 nucleic acids Chemical class 0.000 description 41
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 40
- 125000003275 alpha amino acid group Chemical group 0.000 description 37
- 206010028980 Neoplasm Diseases 0.000 description 34
- 239000000427 antigen Substances 0.000 description 34
- 108091007172 antigens Proteins 0.000 description 34
- 102000038129 antigens Human genes 0.000 description 34
- 210000004881 tumor cells Anatomy 0.000 description 33
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 32
- 102000026088 HLA-A2 Antigen Human genes 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 28
- 201000011510 cancer Diseases 0.000 description 26
- 239000000562 conjugate Substances 0.000 description 21
- 150000002500 ions Chemical class 0.000 description 21
- 231100000765 Toxin Toxicity 0.000 description 20
- 239000003053 toxin Substances 0.000 description 20
- 108020003112 toxins Proteins 0.000 description 20
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 15
- 206010025650 Malignant melanoma Diseases 0.000 description 14
- 201000001441 melanoma Diseases 0.000 description 14
- 102100007124 MTPAP Human genes 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 10
- 102100008453 FOLH1 Human genes 0.000 description 9
- 101700036477 FOLH1 Proteins 0.000 description 9
- 229940079593 drugs Drugs 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 230000003834 intracellular Effects 0.000 description 9
- 230000001225 therapeutic Effects 0.000 description 9
- 206010059512 Apoptosis Diseases 0.000 description 8
- 101700008337 PSMA Proteins 0.000 description 8
- 230000000890 antigenic Effects 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 102000003952 Caspase 3 Human genes 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 6
- 102100011337 KLK4 Human genes 0.000 description 6
- 239000000611 antibody drug conjugate Substances 0.000 description 6
- 108091008116 antibody drug conjugates Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 108010024383 kallikrein 4 Proteins 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 241000713826 Avian leukosis virus Species 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 229960004679 Doxorubicin Drugs 0.000 description 5
- 210000004072 Lung Anatomy 0.000 description 5
- 102100017963 PSCA Human genes 0.000 description 5
- 101700038464 PSCA Proteins 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 235000009168 Coleus dazo Nutrition 0.000 description 4
- 244000016741 Coleus dazo Species 0.000 description 4
- 101700020122 DRB1 Proteins 0.000 description 4
- 101700016627 DRB8 Proteins 0.000 description 4
- 108010075646 HLA-B18 Antigen Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 101700014034 Lcn3 Proteins 0.000 description 4
- 102100006037 MUC1 Human genes 0.000 description 4
- 101700052761 MUC1 Proteins 0.000 description 4
- 210000002307 Prostate Anatomy 0.000 description 4
- 102100001312 RBM45 Human genes 0.000 description 4
- 101700059484 RBM45 Proteins 0.000 description 4
- 108010039491 Ricin Proteins 0.000 description 4
- 101710026336 S5 Proteins 0.000 description 4
- 229940043517 Specific immunoglobulins Drugs 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001332 colony forming Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000009114 investigational therapy Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 230000000051 modifying Effects 0.000 description 4
- 201000009251 multiple myeloma Diseases 0.000 description 4
- 230000002285 radioactive Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010003816 Autoimmune disease Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 108010089239 Gelonium multiflorum GEL protein Proteins 0.000 description 3
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102100009692 MAGEC2 Human genes 0.000 description 3
- 101710027725 MAGEC2 Proteins 0.000 description 3
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 3
- 108010084592 Saporins Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 201000001531 bladder carcinoma Diseases 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000000295 complement Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000003898 interleukin-24 Human genes 0.000 description 3
- 108090000237 interleukin-24 Proteins 0.000 description 3
- 230000002147 killing Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 108010045030 monoclonal antibodies Proteins 0.000 description 3
- 102000005614 monoclonal antibodies Human genes 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 2
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 2
- 244000303258 Annona diversifolia Species 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 102100011431 BAGE Human genes 0.000 description 2
- 108060000856 BAGE Proteins 0.000 description 2
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 2
- 102100008431 CCL26 Human genes 0.000 description 2
- 101700040437 CCL26 Proteins 0.000 description 2
- 102100000189 CD22 Human genes 0.000 description 2
- 101700020617 CD22 Proteins 0.000 description 2
- 102100016493 CD33 Human genes 0.000 description 2
- 101700017647 CD33 Proteins 0.000 description 2
- 101700078950 CD44 Proteins 0.000 description 2
- 102100003735 CD44 Human genes 0.000 description 2
- 102100001891 CTAG1A Human genes 0.000 description 2
- 101710004449 CTAG1A Proteins 0.000 description 2
- 229960004562 Carboplatin Drugs 0.000 description 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102100010782 EGFR Human genes 0.000 description 2
- 101700039191 EGFR Proteins 0.000 description 2
- 101700025368 ERBB2 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010012015 GVYDGREHTV Proteins 0.000 description 2
- 241000702620 H-1 parvovirus Species 0.000 description 2
- 108010036972 HLA-A11 Antigen Proteins 0.000 description 2
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 2
- 102210010945 HLA-DRB1*0901 Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 229940027941 Immunoglobulin G Drugs 0.000 description 2
- 102000004851 Immunoglobulin G Human genes 0.000 description 2
- 108090001095 Immunoglobulin G Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 231100000608 Immunotoxin Toxicity 0.000 description 2
- 108010004484 Immunotoxins Proteins 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940117681 Interleukin-12 Drugs 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 108010059255 MAGE-A10 antigen Proteins 0.000 description 2
- 102100003018 MAGEA1 Human genes 0.000 description 2
- 101710027659 MAGEA1 Proteins 0.000 description 2
- 102100003019 MAGEA2 Human genes 0.000 description 2
- 101710027663 MAGEA2B Proteins 0.000 description 2
- 102100000165 MS4A1 Human genes 0.000 description 2
- 101710010909 MS4A1 Proteins 0.000 description 2
- 102100013951 MUC2 Human genes 0.000 description 2
- 101700036633 MUC2 Proteins 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 2
- 229940043515 Other immunoglobulins in ATC Drugs 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- 108010077397 Pseudomonas aeruginosa toxA protein Proteins 0.000 description 2
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 2
- 210000001550 Testis Anatomy 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001188 anti-phage Effects 0.000 description 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- -1 bicin Chemical class 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000009030 carcinoma Diseases 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 230000003899 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000002962 histologic Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 229960000060 monoclonal antibodies Drugs 0.000 description 2
- 108010093470 monomethyl auristatin E Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- DTYZSEFHBLCMTE-HDIZBSAMSA-N (2R)-2-[[(2S)-6-amino-2-[[(4R)-5-amino-4-[[(2S)-2-[2-[(3R,4R,5S,6R)-3-(carboxyamino)-5-[(2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(2-oxopropyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoyl]amino]-5-oxopentanoyl]am Chemical compound OC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NC(O)=O)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](CC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DTYZSEFHBLCMTE-HDIZBSAMSA-N 0.000 description 1
- SVTBUTPWEOUGGT-UHFFFAOYSA-N 2-[5-[5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2SC(=NN=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 SVTBUTPWEOUGGT-UHFFFAOYSA-N 0.000 description 1
- 102200027838 ADAM19 G4S Human genes 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 101710025507 BTX Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 102100005830 CD70 Human genes 0.000 description 1
- 101700017377 CD70 Proteins 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 102000004041 Caspase 7 Human genes 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 210000003483 Chromatin Anatomy 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101700049441 EBNA3 Proteins 0.000 description 1
- 102000027760 ERBB2 Human genes 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 231100000776 Exotoxin Toxicity 0.000 description 1
- 102100020211 GAGE1 Human genes 0.000 description 1
- 101700009370 GAGE1 Proteins 0.000 description 1
- 101700075868 HER1 Proteins 0.000 description 1
- 108010029526 HLA-A28 antigen Proteins 0.000 description 1
- 108010034115 HLA-A29 antigen Proteins 0.000 description 1
- 108010018475 HLA-A31 antigen Proteins 0.000 description 1
- 108010009256 HLA-B13 Antigen Proteins 0.000 description 1
- 108010070087 HLA-B37 Antigen Proteins 0.000 description 1
- 108010014597 HLA-B44 Antigen Proteins 0.000 description 1
- 108010016670 HLA-C*02 antigen Proteins 0.000 description 1
- 108010070768 HLA-C*03 antigen Proteins 0.000 description 1
- 108010059045 HLA-C*06 antigen Proteins 0.000 description 1
- 108010007655 HLA-C*70 antigen Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 101700082799 IL2RA Proteins 0.000 description 1
- 102100002950 ISG20 Human genes 0.000 description 1
- 101700015336 ISG20 Proteins 0.000 description 1
- 101710030028 IVNS1ABP Proteins 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102100016653 LALBA Human genes 0.000 description 1
- 101700017573 LALBA Proteins 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100003012 MAGEA8 Human genes 0.000 description 1
- 101710027662 MAGEA8 Proteins 0.000 description 1
- 101710028471 MFGE8 Proteins 0.000 description 1
- 102100006993 MFGE8 Human genes 0.000 description 1
- 241000108056 Monas Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100007544 NCAM1 Human genes 0.000 description 1
- 101700077124 NCAM1 Proteins 0.000 description 1
- 101700055840 NSP1N Proteins 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 240000008962 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229950007318 OZOGAMICIN Drugs 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 101710032784 PTHLH Proteins 0.000 description 1
- 102100018056 PTHLH Human genes 0.000 description 1
- 101710018405 PTPN11 Proteins 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 231100000654 Protein toxin Toxicity 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101700028023 RALA Proteins 0.000 description 1
- 101710004267 RPL18 Proteins 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2S,5Z,9R,13E)-13-[2-[[4-[(2E)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 102100002063 SLC45A3 Human genes 0.000 description 1
- 101700067429 SYNO Proteins 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100009538 TNFRSF8 Human genes 0.000 description 1
- 101710040533 TNFRSF8 Proteins 0.000 description 1
- 101700057439 TOXA Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 101700025288 WOX3A Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 101700067277 chxA Proteins 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 201000003963 colon carcinoma Diseases 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 201000010915 glioblastoma multiforme Diseases 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 101710009723 hupB Proteins 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 101700045377 mvp1 Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 108010078110 pokeweed antiviral protein Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108010079891 prostein Proteins 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 101700029718 ral Proteins 0.000 description 1
- 101700002861 ralR Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002476 tumorcidal Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Abstract
Discloses an immunoglobulin linked with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells, wherein said peptide is derived from MAGE and is a peptide that is present in more than one MAGE protein, and wherein the MHC is MHC-1, and wherein said immunoglobulin is an antibody, an antibody fragment or a derivative of an antibody. AGE protein, and wherein the MHC is MHC-1, and wherein said immunoglobulin is an antibody, an antibody fragment or a derivative of an antibody.
Description
ABERRANT CELL-RESTRICTED GLOBULINS
PROVIDED WITH A TOXIC MOIETY
This present application is a divisional application divided out of New Zealand Patent
Application No. 627300.
TECHNICAL FIELD
The invention relates to the field of rapeutics. More specifically, the invention
relates to immunoglobulins provided with a toxic moiety. Even more ically, the
invention relates to human antibodies. The invention also relates to the use of these
biotherapeutics in the ent of a host suffering from a disease associated with
aberrant cells, such as s and autoimmune diseases.
BACKGROUND
The development of immunoglobulin-drug conjugates is one of the drug development
fields that receives high attention nowadays. Humanized or human antibodies are the
largest and most important class of immunoglobulins under investigation for use in
antibody-drug conjugates (ADCs) and in immunotoxins and antibody-radionuclide
conjugates. These antibodies target binding sites (over)expressed at aberrant cells, such
as those exposed in cancers and (auto)immune diseases, and during infections. Many of
the conjugates have a limited degree of efficacy. For example, the maximum tolerated
dose of toxins is relatively low due to their toxicity towards healthy tissue.
Lowering the dose is one way of protecting healthy cells for the non-specific toxic
activity of the toxin or the drug in ADCs. Lowering the dose, however, hampers the
delivery of an efficacious amount of conjugate at the site of for example a tumor. The
unwanted side ons are mainly due to the targeting of the antibodies to binding sites
that are not exclusively exposed by nt cells but also to some extent by healthy cells.
Thus, insufficient specificity for aberrant cells over y cells s desired
efficacy and hampers obtaining the desired safety profiles of the ys
immunoglobulin-drug conjugates.
Toxic moieties currently in the clinic or under investigation are numerous and e
[6]. Amongst the first toxins that were chemically linked to murine antibodies are plant
derived protein toxins and bacterial toxins such as saporin, Diphtheria toxin,
Pseudomonas exotoxin, gelonin, ricin, ricin A chain, abrin and pokeweed antiviral
protein. Other immunoglobulins ed with a toxin moiety comprise single chain Fv
fused at the DNA level with toxins. An example is the inant protein BL22
consisting of the Fv portion of an anti-human CD22 antibody fused to a nt of
Pseudomonas exotoxin-A, that targets B-cell malignancies such as hairy cell leukemia
and non-Hodgkin’s lymphoma. Other examples of immunoglobulins conjugated to
toxins are the antibody-radionuclide conjugates. Human CD20 has been chosen by drug
developers as the target for two monoclonal antibodies, conjugated with 90-Yttrium or
with 131-Iodine, for treatment of non-Hodgkin’s lymphomas. In ts to improve the
tumor selectivity of certain drugs, murine monoclonal antibodies were conjugated to
compounds such as bicin, vinblastine, methotrexate, providing so-called
antibody-drug conjugates. Insufficient tumor cell specificity however still limited the
therapeutic usefulness. Even when selecting tumor cell surface antigens that are (highly)
over-expressed at aberrant cells, still the low expression levels at healthy cells gives rise
to insufficient selectivity of the antibody-drug conjugates. Current cytotoxic umor
drugs under investigation are for example sinoids and atin analogs, that both
target intracellular tubulin, and duocarmycins and eamicins, that target DNA
structure. These compounds are potent in their cytotoxic activtiy, though not ive
for aberrant cells. Antibiotic calicheamicin conjugated to an anti-human CD33
monoclonal antibody was approved and used in the clinic, but was withdrawn due to
serious side effects. Additional examples of drugs currently under investigation for their
potential beneficial use in antibody-drug conjugates meant for the treatment of cellular
aberrancies are ozogamicin, hydrazone-calicheamicin, vedotin, ine, mertansine.
These toxic moieties are conjugated to globulins targeting cell surface s
sed at tumor cells, though also expressed to some extent at healthy cells. Typical
examples of immunoglobulin-drug conjugate-targeted cell surface markers t at
both tumor cells and healthy cells are CD19, CD20, CD22, CD25, CD30, CD33, CD56,
CD70, HER2/neu. All these immunoglobulin-drug conjugate development programs
thus inherently bear the risk for unacceptable safety profiles and consequent poor
efficacy due to low maximum tolerated doses. Conjugating drugs, uclides or toxins
to immunoglobulins specifically and selectively targeting aberrant cells and not targeting
healthy cells would thus provide for therapies with improved specificity and selectivity
for aberrant cells and with an improved safety profile.
Y OF THE INVENTION
The t invention es for an immunoglobulin linked with a toxic moiety,
comprising at least an immunoglobulin variable region that specifically binds to an
MHC-peptide complex preferentially associated with aberrant cells, wherein said e
is derived from MAGE and is a peptide that is present in more than one MAGE protein,
and wherein the MHC is MHC-1, and wherein said immunoglobulin is an antibody, an
antibody fragment or an dy derivative, e.g. a Fab or a ScFV.
In certain ments the immunoglobulin variable region is a Vh or Vhh and
optionally r ses a Vl. In certain cases the immunoglobulin is a human IgG.
The toxic moiety and immunoglobulin may be chemically linked, for e by a
peptide linker. In certain embodiments the toxic moiety is a proteinaceous toxic moiety.
In this case the immunoglobulin linked to the toxic moiety may be encoded at the DNA
level.
The invention also provides for pharmaceutical compositions comprising the
immunoglobulin linked with a toxic moiety as described herein, and a suitable diluent
and/or excipient.
Further provided for is the use of an immunoglobulin linked with a toxic moiety as
described herein, in the manufacture of a medicament for the treatment of a host suffering
from a disease associated with aberrant cells, preferably whereby the toxic moiety is
internalized during said treatment. Also provided is the use of an immunoglobulin linked
with a toxic moiety as described herein, in the manufacture of a ment for the
treatment of a host suffering from a cancer, n at least the toxic moiety is
internalized during said treatment.
DISCLOSURE OF THE INVENTION
ic and selective delivery of a toxic moiety in target aberrant cells demands for
binding molecules specific for binding sites preferentially associated with aberrant cells.
These binding molecules then are used as carriers and transporters of the toxic moieties,
specifically and selectively delivering the toxic moieties at and in the aberrant cells. We
here disclose immunoglobulin-drug conjugates comprising these preferred features. The
immunoglobulins in the immunoglobulin-drug conjugates of the invention se
immunoglobulin binding regions with improved selectivity for aberrant cells by
specifically binding to binding sites preferentially associated with these aberrant cells.
We disclose as red targets for the antibody of the invention, intracellular ns
that are associated with aberrant cells. These proteins are available as peptides presented
by MHC on the e of aberrant cells. The use of MHC-peptide complexes as targets
opens us a new field of tumor s, because so far typically targets associated with the
surface of nt cells have been envisaged. Although it is preferred that the target is
specific for nt cells (tumor cells) in many cases upregulated intracellular ns
are also suitable for at least ing the therapeutic window of immunotoxins. Our
most preferred targets are peptides derived from MAGE presented in the context of
MHC-1. In particular MAGE peptides that are present in more than one MAGE protein
(multi-MAGE epitope; see WO2012/091564 incorporated herein by reference).
The toxic moiety according to the invention is preferably a drug compound, a
radionuclide or a toxin. The toxic moiety according to the invention is a nonproteinaceous
molecule or a proteinaceous molecule. In the immunoglobulin-drug
conjugates of the invention, the toxic moiety is preferably ated by chemical
conjugation. Also preferred are immunoglobulins of the invention fused at the DNA level
to a proteinaceous toxic moiety.
The immunoglobulins in the immunoglobulin-drug conjugates of the invention are
suitable for the specific and selective localization of a toxic effect inside targeted aberrant
cells, leaving healthy cells essentially cted. Immunoglobulins comprise
immunoglobulin binding domains, referred to as immunoglobulin variable domains,
sing immunoglobulin variable regions. Maturation of immunoglobulin variable
regions results in variable domains adapted for specific binding to a target binding site.
Immunoglobulins are therefore particularly suitable for providing the immunoglobulindrug
conjugates of the invention with the y to specifically and selectively target
aberrant cells. At their surface, aberrant cells present aberrant cell-associated antigen
peptides in the context of major histocompatibility complex (MHC). ore, for the
immunoglobulins in the globulin-drug conjugates of the invention, aberrant cellassociated
MHC-1 peptide complexes are a preferred target on nt cells. In addition,
aberrant cell-associated MHC-2 peptide xes are valuable targets on e.g. tumors of
hematopoietic , for the immunoglobulins in the globulin-drug conjugates
of the invention. The present invention therefore provides immunoglobulins in
immunoglobulin-drug conjugates, with improved specificity and ivity for aberrant
cells by targeting MHC-peptide complexes which are preferentially associated with
aberrant cells. This improved specificity and selectivity for aberrant cells is accompanied
with a reduced level of unintentional targeting of y cells by the immunoglobulins
in the immunoglobulin-drug conjugates of the invention. Most preferably, healthy cells
are not targeted by the immunoglobulin-drug conjugates of the invention. Thus, in a first
embodiment the invention provides an globulin provided with a toxic moiety,
sing at least an immunoglobulin variable region that ically binds to an
MHC-peptide complex entially associated with aberrant cells. Preferred
immunoglobulins of the invention are antibodies, but fragments and/or derivatives such
as Fab and/or ScFv can also be used. Even more preferred immunoglobulins of the
ion are antibodies of the globulin G (IgG) type. Other immunoglobulins
of the invention are for example heavy-chain (only) antibodies comprising Vh or Vhh
and IgA, and their fragments such as Fab fragments, and Fab fragments of IgG’s.
globulins bind via their immunoglobulin variable s to binding sites on
molecules, such as epitopes, with a higher binding affinity than background interactions
between molecules. In the context of the invention, background interactions are typically
interactions with an affinity lower than a KD of 10E-4 M. Immunoglobulin variable
domains in light chains (Vl) and immunoglobulin variable domains in heavy chains (Vh)
of antibodies typically comprise the nt-cell specific immunoglobulin variable
regions of the invention. Thus, in one embodiment the invention provides an
immunoglobulin provided with a toxic moiety, comprising at least an immunoglobulin
variable region, wherein said immunoglobulin variable region is a Vh(h) that specifically
binds to an MHC-peptide complex preferentially associated with aberrant cells. Thus, in
yet another embodiment the invention also provides an immunoglobulin provided with a
toxic moiety, comprising at least an immunoglobulin variable , wherein said
immunoglobulin le region is a Vh that specifically binds to an MHC-peptide
complex preferentially associated with aberrant cells, and wherein said immunoglobulin
variable region further comprises a Vl.
As said, immunoglobulins G are particularly suitable binding molecules for use in
therapies specifically and selectively targeting aberrant cells, for site-specific ry of
a toxic moiety according to the invention. Because the anticipated predominant use of
the antibodies of the invention is in therapeutic treatment regimes meant for the human
body, in a particular embodiment of the invention, the immunoglobulins provided with a
toxic moiety have an acid sequence of human . Thus, in one embodiment
the invention provides a human IgG provided with a toxic moiety, comprising at least an
immunoglobulin variable region, wherein said immunoglobulin variable region is a Vh
that specifically binds to an MHC-peptide complex preferentially ated with
aberrant cells, and wherein said immunoglobulin variable region further comprises a Vl.
Of course, humanized antibodies, with the precursor antibodies encompassing amino
acid sequences originating from other species than human, are also part of the ion.
Also part of the invention are chimeric antibodies, comprising (parts of) an
immunoglobulin variable region according to the ion ating from a species
other than human, and grafted onto a human antibody.
An aberrant cell is defined as a cell that deviates from its y normal counterparts.
Aberrant cells are for example tumor cells, cells invaded by a pathogen such as a virus,
and autoimmune cells.
Thus, in one embodiment the invention provides an immunoglobulin ing to any of
the aforementioned embodiments wherein the MHC-peptide complex is specific for
aberrant cells.
In the molecules of the invention the toxic es are preferably chemically linked to
the immunoglobulins via any linker try know in the art, and ally via an
additional spacer. According to the invention, one or several, preferably two to six toxic
moiety molecules are chemically linked to an immunoglobulin molecule of the invention.
The number of conjugated toxic moiety molecules per single immunoglobulin molecule
is restricted by boundaries such as the number of available sites for conjugation on the
globulin, the stability of the conjugate, the preservation of the ability of the
immunoglobulin to specifically bind to an aberrant cell, etc. Of course, also two, three,
etc. different toxic moieties can be linked to an immunoglobulin, depending amongst
others on available binding sites and the applied linker chemistry. Chemical linking of
the toxic es has several advantages when working with immunoglobulins. This
way, toxic moieties cannot interfere with expression, folding, assembly and secretion of
the immunoglobulin molecules. Thus, in one embodiment the invention provides an
immunoglobulin according to any of the aforementioned embodiments wherein the toxic
moiety is chemically linked to the globulin. It is then also part of the current
ion that toxic moieties are covalently bound via peptide bonds, and ably via
a peptide linker, to the immunoglobulins of the invention. The toxic moiety and the
immunoglobulin are then fused at the DNA level. Thus, in one embodiment the invention
provides an immunoglobulin according to any of the aforementioned embodiments
wherein the toxic moiety is a protein, preferably fused to the immunoglobulin at the DNA
level, ably through a linker sequence. In many instances a simple Gly-Ser linker of
4-15 amino-acid residues may suffice, but if r flexibility between the
immunoglobulin and the toxic moiety is desired longer or more x linkers may be
used. Preferred linkers are (Gly4Ser)n,
(GlySerThrSerGlySer)n,GlySerThrSerGlySerGlyLysProGlySerGlyGluGlySerThrLysGl
y, GlyPheAlaLysThrThrAlaProSerValTyrProLeuAlaProValLeuGluSerSerGlySerGly or
any other linker that provides flexibility allowing protein folding, stability t
undesired proteolytic activity and flexibility for the immunoglobulins of the invention to
exert their activity. Another group of preferred linkers are linkers based on hinge regions
of immunoglobulins. These linkers tend to be quite flexible and quite resistant to
proteases. The most red linkers based on hinge regions are
LysSerCysAspLysThrHisThr (linking Ch1 and Ch2 in IgG1),
GluLeuLysThrProLeuGlyAspThrThrHisThr (IgG3), and GluSerLysTyrGlyProPro
(IgG4). Thus, the role of any applied chemical linker in conjugates according to the
ion or the role of any applied peptide linker in fused molecules according to the
ion is aiding the dual activity of the antibodies of the invention, i.e. specific and
selective binding of the globulin to aberrant cells, and subsequent ry of at
least the toxic moiety in the targeted aberrant cells. Thus, in one embodiment the
invention provides the use of an immunoglobulin provided with a toxic moiety according
to any of the aforementioned embodiments, for the treatment of a host suffering from a
disease associated with aberrant cells. In a further embodiment the invention provides
the use of an immunoglobulin provided with a toxic moiety ing to any of the
aforementioned embodiments, for the treatment of a host suffering from a disease
associated with aberrant cells wherein at least the toxic moiety is internalized into the
aberrant cell. According to the invention, the immunoglobulins provided with a toxic
moiety are for example used for the treatment of cancer. Thus, in a red embodiment
the invention provides an immunoglobulin provided with a toxic moiety according to any
of the aforementioned embodiments for use in the treatment of cancer.
Preferred toxic moieties according to the invention are numerous. Several examples of
preferred toxic moieties according to the invention are drugs such as doxorubicin,
cisplatin, carboplatin, vinblastine, methotrexate, chelated radioactive metal ions,
(synthetic) antineoplastic agents such as monomethyl auristatin E, radioactive iodine,
radionuclides such as rium, 131-Iodine, to name a few, which are chemically
conjugated to the immunoglobulins of the invention. Also preferred toxic es
according to the invention are proteinaceous toxins such as a fragment of Pseudomonas
exotoxin-A, statins, ricin A, gelonin, saporin, interleukin-2, interleukin-12, viral proteins
, apoptin and NS1, and ral proteins HAMLET, TRAIL and mda-7. Thus, in
one embodiment of the invention, antibodies are provided for the specific targeting of
aberrant cells, wherein the toxic moiety is selected from the list of available toxic
moieties comprising toxins such as a fragment of monas exotoxin-A, statins,
chelated radioactive metal ions, radioactive iodine, ricin A, gelonin, saporin, interleukin-
2, interleukin-12, radionuclides such as 90-Yttrium, 131-Iodine, drugs such as
doxorubicin, taxol or derivatives, 5-FU, anthracyclines, vinca alkaloids, calicheamicins,
cisplatin, carboplatin, stine, methotrexate, (synthetic) antineoplastic agents such as
monomethyl auristatin E, n, parvovirus-H1 NS1 n, E4orf4, TRAIL, mda-7,
HAMLET.
According to the invention proteinaceous molecules are molecules comprising at least a
string of amino acid es. In addition, ing to the invention the proteinaceous
molecules may se ydrates, disulphide bonds, phosphorylations,
sulphatations, etc.
When antibodies of the invention are designed to first bind to a target nt cell,
followed by internalization, the toxic moiety can then subsequently have its intracellular
(cytotoxic) function, i.e. inducing apoptosis.
For administration to subjects the antibodies of the invention must be formulated.
Typically these dies will be given erally. For formulation simply water
(saline) for injection may suffice. For stability reasons more x formulations may
be necessary. The invention contemplates lyophilized itions as well as liquid
compositions, provided with the usual additives. Thus, in one embodiment the invention
es a pharmaceutical composition comprising an immunoglobulin provided with a
toxic moiety according to any of the aforementioned embodiments and suitable diluents
and/or excipients.
The dosage of the antibodies of the invention must be ished through animal studies,
(cell-based) in vitro studies and al studies in so-called rising-dose experiments.
lly, the doses will be comparable with present day antibody dosages (at the molar
level). Typically, such dosages are 3-15 mg/kg body weight, or 25-1000 mg per dose.
In addition, especially in the more difficult to treat cellular aberrancies the first
applications of the antibodies of the invention will (at least initially) probably take place
in combination with other treatments (standard care). Of course, the invention also
provides antibodies for use in novel or first treatments of any malignancy accompanied
by the occurrence of aberrant cells, for which current treatments are not efficient enough
or for which currently no treatment options are available. Thus, for example the invention
also provides a pharmaceutical composition comprising an invented immunoglobulin
ed with a toxic moiety and a conventional atic and/or tumoricidal agent.
Moreover, the t invention also provides a ceutical composition comprising
an ed immunoglobulin provided with a toxic moiety for use in an adjuvant
treatment of cancer. Thus, in one embodiment of the invention, an invented
immunoglobulin provided with a toxic moiety for use in an adjuvant treatment of cancer
is provided. Additionally, the current invention also provides a pharmaceutical
composition sing an invented immunoglobulin provided with a toxic moiety for
use in a combination chemotherapy treatment of cancer. Examples of chemotherapeutical
treatments that are combined with the ceutical composition of the current
invention are etoposide, paclitaxel, cisplatin, doxorubicin and methotrexate.
The pharmaceutical compositions according to the invention will lly find their use
in the treatment of cancer, particularly in forms of cancer where the targets of the
preferred antibodies of the invention (complexes of MHC and tumor-specific antigen
es) are presented by the tumors. Table 1, for example, gives a list of tumors on
which complexes of MHC and MAGE-A peptides have been found. It is easy using an
antibody of the invention to identify tumors that present these target MHC-peptide
complexes. This can be done in vitro or in vivo (imaging).
It is preferred that the cell-surface molecules comprising the binding sites for the
dies of the invention are internalized into the targeted aberrant cell, together with
the antibodies of the invention, or together with at least the toxic moiety of the antibodies
of the invention. In a particularly preferred embodiment of the invention the targeted
aberrant cells go into apoptosis as a result of said internalization. Thus, in one
embodiment the invention es the use of an globulin ed with a toxic
moiety according to any of the aforementioned embodiments, for the treatment of a host
suffering from cancer, wherein at least the toxic moiety is alized into the aberrant
cell.
The invention of course also comprises a nucleic acid le encoding the
immunoglobulin part of an antibody ing to any of the embodiments of the
invention, when the toxic moiety is chemically linked to the immunoglobulin in the
antibody of the invention. Thus, the invention also comprises a nucleic acid molecule
encoding an immunoglobulin and a toxic moiety according to any of the embodiments
of the invention, when the toxic moiety is fused to the immunoglobulin at the DNA level.
These molecules according to the invention can be ed in yotes or
eukaryotes. The codon usage of prokaryotes may be different from that in eukaryotes.
The nucleic acids according to the invention can be adapted in these respects. Also,
ts that are ary for secretion may be added, as well as promoters, terminators,
enhancers etc. Also, elements that are necessary and/or beneficial for the isolation and/or
purification of the immunoglobulins of the invention or of the antibodies of the invention
may be added. Typically, the nucleic acids according to the invention are provided in an
expression vector suitable for the host in which they are to be produced. Choice of a
production platform will depend on the size of the molecule, the expected issues around
protein folding, whether amino-acid sequences are present in the immunoglobulin or in
the antibody that require glycosylation, expected issues around isolation and/or
purification, etc. For example, the presence of disulfide bonds in immunoglobulins or
naceous toxins of the invention will typically guide the selection of the preferred
production platform. Thus, typically nucleic acids according to the invention are adapted
to the production and purification platform in which the immunoglobulins optionally
with their fused proteinaceous toxins of the invention are to be produced. Thus, the
ion provides a vector comprising a nucleic acid molecule ng an
immunoglobulin or an antibody of the invention. For stable expression in an eukaryote
it is red that the nucleic acid ng the immunoglobulin or the antibody of the
invention is integrated in the host cell genome (at a suitable site that is not silenced). In
one embodiment the invention therefore comprises: a vector comprising means for
integrating the nucleic acid in the genome of a host cell. The invention further comprises
the host cell or the organism in which the nucleic acid molecule encoding for the
immunoglobulin of the ion optionally with their fused proteinaceous toxins, is
present and which is thus capable of producing the immunoglobulin ally with their
fused proteinaceous toxins of the invention. Thus, in a red embodiment the
invention comprises a cell comprising a nucleic acid molecule according to the invention,
preferably integrated in its genome and/or a vector according to the invention,
comprising a c acid molecule encoding an globulin optionally with their
fused proteinaceous toxins of the invention.
Included in the present invention is also a method for ing an immunoglobulin
optionally with their fused proteinaceous toxins of the ion, comprising culturing a
cell according to the invention, comprising a nucleic acid molecule encoding an
immunoglobulin optionally with their fused proteinaceous toxins of the invention,
preferably integrated in the cell’s genome and/or a vector according to the ion,
comprising a nucleic acid molecule encoding an immunoglobulin optionally with their
fused proteinaceous toxins of the invention, allowing for expression of the
immunoglobulin optionally with their fused proteinaceous toxins and separating the
immunoglobulin optionally with their fused proteinaceous toxins from the culture.
In one embodiment of the invention the immunoglobulin variable domains in the
molecules of the invention target one binding site. Also according to the invention, bispecific
immunoglobulins provided with a toxic moiety are provided that are specifically
binding to two different binding sites associated with the cell surface of nt cells.
By targeting with a single antibody of the invention two different binding sites on an
aberrant cell such as a tumor cell, the risk that both targets are also jointly present on a
healthy cell is significantly r diminished. The ty of the antibodies of the
invention for the two different target binding sites separately, preferably is designed such
that Kon and Koff are very much skewed towards binding to both different binding sites
simultaneously. Thus, the specificity of the bi-specific antibodies of the invention is
sed by increasing their specificity for binding to two different binding sites
associated with aberrant cells. Thus, in one ment of the ion, the dy
according to any of the us embodiments is a hetero-dimeric bi-specific
immunoglobulin G or heavy-chain only dy comprising two different but
complementary heavy chains. The two different but complementary heavy chains may
then be dimerized through their respective Fc regions. Upon applying preferred pairing
mistry, hetero-dimers are preferentially formed over homo-dimers. For example,
two different but complementary heavy chains are subject to forced pairing upon
applying the “knobs-into-holes” CH3 domain engineering technology as described
[Ridgway et al., Protein Engineering, 1996 (ref. 14)]. In a preferred embodiment of the
invention the two different immunoglobulin variable regions in the bi-specific
immunoglobulins of the invention specifically bind to an MHC-peptide complex
preferentially associated with aberrant cells.
l preferred antibodies of the invention are exemplified by the antibodies outlined
in this section, in Figure 5B, and by the examples provided below and in the Examples
section. Thus the invention provides an immunoglobulin provided with a toxic moiety
according to Figure 5B.
One aspect of the invention relates to a method for providing the antibodies of the
invention. As described herein above, it typically es providing a nucleic acid
construct encoding the desired globulin part of antibodies of the invention, or
encoding the desired immunoglobulin fused to a proteinaceous toxic moiety. Said nucleic
acid construct can be uced, preferably via a plasmid or expression vector, into a
prokaryotic host cell and/or in a plant cell and/or in a eukaryotic host cell capable of
sing the construct. In one embodiment, a method of the invention to provide an
immunoglobulin or to e an immunoglobulin fused to a proteinaceous toxic moiety
comprises the steps of providing a host cell with the nucleic acid(s) encoding said
immunoglobulin or said globulin fused to a proteinaceous toxic moiety, and
allowing the expression of said nucleic acid(s) by said host cell.
It is part of the invention that nucleic acids coding for selected (human) immunoglobulin
Vh(h) domains ing to any of the above embodiments are combined with nucleic
acids coding for human immunoglobulin heavy chain constant domains, providing
nucleic acid molecules of the invention encoding for a heavy chain of a human antibody.
The human antibody heavy chain protein t of such a nucleic acid le of the
invention, then may be hetero-dimerized with a universal human antibody light chain. It
is also part of the invention that nucleic acids coding for (jointly) selected human
immunoglobulin Vl domains and Vh domains according to any of the above
embodiments are combined with c acids coding for a human immunoglobulin light
chain constant domain and are combined with nucleic acids coding for human
immunoglobulin heavy chain constant domains, respectively, ing nucleic acid
les of the invention encoding for a light chain and for a heavy chain of a human
antibody. In yet another embodiment of the ion, the nucleic acids coding for the
complementarity determining regions 1, 2 and 3 (CDR1, CDR2, CDR3), forming
together the immunoglobulin variable region of a selected immunoglobulin Vh domain
and/or a selected immunoglobulin Vl domain according to any of the above embodiments
are combined with nucleic acids coding for human immunoglobulin Vh domain frame
work regions and/or human immunoglobulin Vl domain frame work regions,
respectively, ing nucleic acid les of the invention encoding for a heavy
chain variable domain (Vh) of a human antibody and/or encoding for a light chain
variable domain (Vl) of a human antibody (A method known in the art as ‘grafting’).
These nucleic acid molecules encoding for variable domains Vh and/or Vl are, as part of
the invention, then combined with nucleic acids coding for human immunoglobulin
constant s, providing a nucleic acid molecule encoding for a human antibody
heavy chain and/or providing a nucleic acid molecule encoding for a human antibody
light chain.
According to the invention, immunoglobulins or immunoglobulins fused to a
naceous toxic moiety are for example sed in plant cells, eukaryotic cells or
in prokaryotic cells. Non-limited examples of suitable expression systems are tobacco
plants, Pichia pastoris, Saccharomyces cerevisiae. Also ree recombinant protein
production rms are suitable. Preferred host cells are bacteria, like for example
bacterial strain BL21 or strain SE1, or mammalian host cells, more preferably human
host cells. Suitable mammalian host cells include human embryonic kidney (HEK-293)
cells, PerC6 cells or preferably Chinese hamster ovary (CHO) cells, which can be
cially obtained. Insect cells, such as S2 or S9 cells, may also be used using
baculovirus or insect cell expression vectors, although they are less suitable when the
globulins or the fused immunoglobulins-toxic moiety molecules ing to the
invention include elements that involve glycosylation. The produced immunoglobulins
or fused immunoglobulin-toxic moiety molecules according to the invention can be
extracted or isolated from the host cell or, if they are secreted, from the culture medium
of the host cell. Thus, in one embodiment a method of the invention comprises providing
a host cell with one or more nucleic acid(s) encoding said immunoglobulin or said fused
immunoglobulin-toxic moiety molecule, allowing the expression of said nucleic acids by
said host cell. In another preferred embodiment a method of the invention comprises
providing a host cell with one or more nucleic acid(s) encoding two or more different
globulins or two or more different fused immunoglobulin-toxic moiety
molecules, allowing the expression of said c acids by said host cell. For e,
in one embodiment, nucleic acids encoding for a so-called universal immunoglobulin
light chain and nucleic acids encoding for two or more different immunoglobulin heavy
chains are provided, enabling isolation of mono-specific immunoglobulins or ecific
fused immunoglobulin-toxic moiety molecules comprising imers of
heavy chains and/or enabling isolation of bi-specific immunoglobulins or bi-specific
fused immunoglobulin-toxic moiety molecules comprising hetero-dimers of heavy
chains, with all different heavy chains complexed with a universal light chain. Methods
for the recombinant expression of (mammalian) proteins in a (mammalian) host cell are
well known in the art.
As said, it is preferred that the immunoglobulins of the invention are linked with the toxic
moieties via bonds and/or binding interactions other than peptide bonds. Methods for
linking proteinaceous molecules such as immunoglobulins to other proteinaceous
molecules or non-proteinaceous molecules are numerous and well known to those skilled
in the art of protein linkage chemistry. n linkage chemistry not based on peptide
bonds can be based on covalent interactions and/or on non-covalent interactions. A
typical example of linkage chemistries applicable for linking toxic moieties to
immunoglobulins of the invention are the various ations of the Universal Linkage
System sed in patent ations WO92/01699, WO96/35696, 5304,
WO03040722.
As will be clear, an antibody of the invention finds its use in many therapeutic
applications and non-therapeutic applications, e.g. diagnostics, or scientific applications.
Antibodies of the invention, or more preferably the immunoglobulin part of the
antibodies of the invention, suitable for diagnostic purposes are of ular use for
monitoring the expression levels of les exposing g sites on aberrant cells
that are targeted by antibodies of the invention. In this way, it is red whether the
therapy remains efficacious or whether other antibodies of the invention targeting one or
two ent binding sites on the aberrant cells should be applied instead. This is
beneficial when the expression levels of the first or the first two targeted binding site(s)
are below a certain threshold, whereas another or new binding sites (still) can serve as
newly targeted binding sites for antibodies of the invention comprising the appropriate
specific immunoglobulin variable regions for these alternative binding site(s).
Antibodies of the invention may also be used for the detection of (circulating) tumor
cells, and for the -cell ic delivery of immune-stimulatory molecules. For these
later two uses, the sole immunoglobulins of the invention without the fused or conjugated
toxic moiety may also be used.
ed herein is a method for inducing ex vivo or in vivo a modulating effect on a
biological process in a target cell, comprising contacting said cell with an antibody of the
invention in an amount that is effective to induce the modulating effect. Preferably, the
antibody of the invention is used for a modulating effect on a biological process of
aberrant cells in a subject, more preferably a human subject. For therapeutic applications
in humans it is of course preferred that an antibody of the invention does not contain
amino acid sequences of non-human origin. More preferred are antibodies of the
invention, which only contain human amino acid sequences. Therefore, a therapeutically
effective amount of an dy of the invention capable of izing and binding to
one or two disease-specific binding sites and subsequently inducing a modulating effect
on a biological process in the cell, can be stered to a t to ate
ation of aberrant cells expressing the binding site(s) without affecting the viability
of (normal) cells not expressing said disease-specific binding site(s). The specific killing
of aberrant cells while minimizing or even avoiding the deterioration or even death of
healthy cells will generally improve the therapeutic outcome of a patient after
administration of the antibodies of the invention.
Accordingly, also provided is the use of an antibody of the invention as medicament. In
another aspect, the invention provides the use of an antibody of the invention for the
manufacture of a medicament for the treatment of cancer, autoimmune disease, infection
or any other disease of which the symptoms are reduced upon targeting nt cells
expressing disease-specific binding sites with antibodies of the invention. For example,
an antibody of the invention is advantageously used for the manufacture of a medicament
for the treatment of s cancers (e.g. solid , hematologic malignancies).
An e of a red antibody of the invention is an antibody comprising at least
an immunoglobulin variable region specifically binding to the complex between MHC-
1 HLA-0201 and a multi-MAGE-A epitope, conjugated with a toxic moiety, using for
example Universal e System linker chemistry for conjugation. A second example
of a preferred antibody of the invention is an antibody comprising at least an
immunoglobulin variable region specifically binding to the complex between MHC-1
HLA-CW7 and a multi-MAGE-A epitope, conjugated with a toxic moiety, using for
example Universal Linkage System linker chemistry for conjugation. With the bispecific
antibodies of the invention, difficult to target and/or ult to reach aberrant
cells have a higher chance of being ‘hit’ by at least one of the two different
immunoglobulin variable regions in the cific antibodies of the invention, y
providing at least in part the therapeutic activity. An example of a preferred bi-specific
antibody of the ion is an globulin comprising an immunoglobulin variable
region specific for the complex between MHC-1 HLA-0201 and a multi-MAGE-A
e and comprising a second immunoglobulin variable region specific for the
complex between MHC-1 HLA-CW7 and a second multi-MAGE-A e, conjugated
with a toxic .
Antibody fragments of human origin can be isolated from large antibody repertoires
displayed by phages. One aspect of the invention, known by the art, is the use of human
antibody phage display libraries for the selection of human antibody fragments specific
for a selected binding site, e.g. an epitope. Examples of such libraries are phage libraries
comprising human Vh repertoires, human Vh-Vl repertoires, human Vh-Ch1 or human
antibody Fab fragment repertoires.
Although the invention contemplates many different combinations of MHC and
antigenic peptides the most preferred is the combination of MHC-1 and an antigenic
peptide from a tumor related antigen presented by said MHC-1, exclusively expressed
by aberrant cells and not by healthy cells. Because of HLA restrictions, there are many
combinations of MHC-1 – peptide complexes as well as of MHC-2 – peptide complexes
that can be designed based on the rules for presentation of peptides in MHC. These rules
e size limits on peptides that can be ted in the context of MHC, restriction
sites that need to be present for processing of the antigen in the cell, anchor sites that
need to be present on the peptide to be presented, etc. The exact rules differ for the
different HLA classes and for the different MHC classes. We have found that MAGE
derived peptides are very suitable for presentation in an MHC context. An MHC-1
table antigenic peptide with the sequence Y-L-E-Y-R-Q-V-P-G in MAGE-A
[SEQ-ID 3] was identified, that is present in almost every MAGE-A variant (multi MAGE
peptide) and that will be presented by one of the most prevalent MHC-1 s in the
ian population (namely HLA-A0201). A second MAGE peptide that is presented
by another MHC-1 allele (namely HLA-CW7) and that is present in many MAGE
variants, like for e MAGE-A2, -A3, -A6 and -A12, is E-G-D-C-A-P-E-E-K
D 4]. These two combinations of MHC-1 and MAGE peptides together would
cover 80% of the Caucasian population. The same approach can be ed for other
MHC molecules, other HLA restrictions and other antigenic es derived from
tumor-associated antigens. Relevant is that the chosen antigenic peptide to elicit the
response to must be presented in the context of an MHC molecule and recognized in that
context only. Furthermore, the antigenic peptide must be derived from a sufficiently
tumor specific antigen and the HLA restriction must occur in a relevant part of the
population. One of the important advantages of the present invention is that tumors that
down regulate their targeted ptide complex, can be d with a second
immunoglobulin comprising at least one variable region binding to a different MHC-
peptide complex based on the same antigen. If this one is down regulated a third one will
be available. For heterozygotes six different targets on MHC-1 may be ble. Since
cells need to be “inspected” by the immune system from time to time, escape through
down regulation of all MHC molecules does not seem a viable escape route. In the case
that MAGE is the antigen from which the peptide is derived escape through down
regulation of the antigen is also not possible, because MAGE seems important for
survival of the tumor [8]. Thus the present invention, in an ant aspect reduces or
even prevents escape of the tumor from the therapy. Thus the invention es in a
preferred embodiment an antibody of the invention y the globulin
variable region is capable of binding to an MHC-I – peptide complex. In a further
preferred embodiment the invention es an globulin y the
immunoglobulin variable region is capable of binding to MHC-I – peptide complexes
comprising an antigenic peptide derived from a tumor related antigen, in particular
MHC-I – peptide complexes comprising an antigenic peptide t in a variety of
MAGE antigens, y the immunoglobulin is provided with a toxic moiety.
Because in one embodiment the invention uses MHC molecules as a target, and
individuals differ in the bility of MHC targets, the invention also provides a socalled
companion diagnostic to determine the HLA composition of an dual.
Although the invention preferably uses a more or less universal (MAGE) peptide, the
invention also provides a diagnostic for determining the expression of the particular
antigen by the tumor. In this manner the therapy can be geared to the patient
(personalized medicine, patient stratification), particularly also in the set-up to prevent
escape as described herein before. It is known that the HLA restriction patterns of the
Asian tion and the black population are different from the Caucasian population.
For different populations different MHC-peptide complexes can be targeted.
Although the present specification presents more specific disclosure on tumors, it must
be understood that other aberrant cells can also be targeted by the antibodies of the
t invention. These other aberrant cells are typically cells that also erate
without sufficient control. This occurs in autoimmune diseases. It is typical that these
cells start to show expression of tumor ns. In particular MAGE polypeptides have
been identified in toid arthritis [7].
In literature it is shown that a single nine amino-acid (A.A.) peptide present in MAGEA2
, -A3, -A4, -A6, -A10, and -A12 is presented by HLA-A0201 on tumor cells, and can
be recognized by cytotoxic T-lymphocytes [1]. This nine amino acid residues peptide
with sequence Y-L-E-Y-R-Q-V-P-G [SEQ-ID 3] is almost identical to the HLA-A0201
presented MAGE-A1 peptide Y-L-E-Y-R-Q-V-P-D [SEQ-ID 5], except for the anchor
residue at position 9. Replacement of the anchor residue with Valine results in a 9 amino
acid es peptide with enhanced g capacity to HLA-A0201 molecules [1].
Human and mouse T-lymphocytes recognizing the Y-L-E-Y-R-Q-V-P-V [SEQ-ID 6]
peptide presented by 01 also recognize the original MAGE-A Y-L-E-Y-R-Q-VP-G
and Y-L-E-Y-R-Q-V-P-D es presented on tumors of distinct origin. As diverse
tumors may each express at least one MAGE-A gene, targeting of this so-called multi-
MAGE-A epitope es the vast majority of tumors. As an example, MAGE-A
expression in human prostate tumor cell lines and in human xenographs was analyzed
and shown to be highly diverse, but in each individual sample tested at least one MAGEA
gene was expressed (Table 2), confirming that targeting this multi-MAGE-A epitope
serves as a universal HLA-A0201 restricted target for therapy.
Of course l other multi-MAGE or multi-target epitopes may be designed. In
principle the invention contemplates combinations of tumor specific antigen derived
MHC presented epitopes in different HLA restrictions of both MHC-I and MHC-II,
ed by immunoglobulins linked to a toxic moiety, to induce apoptosis in aberrant
cells. Examples of MHC - MAGE peptide co mbinations that can be targeted by
antibodies of the invention are peptide IMPKAGLLI (MAGE-A3) [SEQ-ID 8] and HLADP4
or peptide 243-KKLLTQHFVQENYLEY-258 (MAGE-A3) [SEQ-ID 9] and HLA-
DQ6. Other non-limiting examples of tumor specific complexes of HLA and antigen
peptide are: HLA A1 – 1 peptide EADPTGHSY [SEQ-ID 10], HLA A3 –
1 SLFRAVITK [SEQ-ID 11], HLA A24 – 1 NYKHCFPEI [SEQ-ID
12], HLA A28 – MAGE-A1 EVYDGREHSA [SEQ-ID 13], HLA B37 – MAGEA1
/A2/A3/A6 REPVTKAEML [SEQ-ID 14], expressed at aberrant cells related to
melanoma, breast carcinoma, SCLC, sarcoma, NSCLC, colon carcinoma (Renkvist, N.
et al., Cancer Immunol. Immunother. (2001) V50:3-15 (ref. 13)). Further examples are
HLA B53 – MAGE-A1 DPARYEFLW [SEQ-ID 15], HLA Cw2 – MAGE-A1
SAFPTTINF [SEQ-ID 16], HLA Cw3 – MAGE-A1 SAYGEPRKL [SEQ-ID 17], HLA
Cw16 – MAGE-A1 SAYGEPRKL D 18], HLA A2 – MAGE A2 KMVELVHFL
[SEQ-ID 19], HLA A2 – 2 YLQLVFGIEV [SEQ-ID 20], HLA A24 – MAGEA2
EYLQLVFGI [SEQ-ID 21], HLA-A1 – MAGE-A3 EADPIGHLY [SEQ-ID 22],
HLA A2 – MAGE-A3 FLWGPRALV [SEQ-ID 23], HLA B44 – MAGE-A3
MEVDPIGHLY [SEQ-ID 24], HLA B52 – MAGE-A3 WQYFFPVIF D 25],
HLA A2 – MAGE-A4 GVYDGREHTV [SEQ-ID 26], HLA A34 – 6
GPR [SEQ-ID 27], HLA A2 – MAGE-A10 GLYDGMEHL [SEQ-ID 28],
HLA Cw7 – MAGE-A12 VRIGHLYIL [SEQ-ID 29], HLA Cw16 – BAGE
AARAVFLAL [SEQ-ID 30], sed by for example melanoma, bladder carcinoma,
NSCLC, sarcoma, HLA A2 – -10 FLWGPRAYA D 31], expressed by
for example skin tumors, lung carcinoma, ovarian carcinoma, mammary carcinoma,
HLA Cw6 – GAGE-1/-2/-8 YRPRPRRY [SEQ-ID 32], HLA A29 – /-4/-5/-6/-
7B YYWPRPRRY [SEQ-ID 33], both expressed by for example melanoma, ia
cells, bladder carcinoma, HLA B13 – NA88-A MTQGQHFLQKV [SEQ-ID 34],
expressed by melanoma, HLA A2 – NY-ESO-1 SLLMWITQCFL [SEQ-ID 35], HLA
A2 – -1a SLLMWITQC [SEQ-ID 36], HLA A2 - NY-ESO-1a QLSLLMWIT
[SEQ-ID 37], HLA A31 – NY-ESO-1a ASGPGGGAPR [SEQ-ID 38], the latter four
expressed by for example melanoma, sarcoma, B-lymphomas, prostate carcinoma,
n carcinoma, bladder carcinoma.
The invention is further exemplified by the non-limiting Examples provided below.
Abbreviations used
A.A., amino acid; Ab, antibody; 2-M, CDR, complementarity determining region;
CHO, Chinese hamster ovary; CT, cancer testis antigens; CTL, cytotoxic T-lymphocyte;
E4orf4, irus early region 4 open reading frame; EBV, Epstein-Barr virus; ELISA,
enzyme linked immunosorbent assay; HAMLET, human α-lactalbumin made lethal to
tumor cells; HEK, human embryonic kidney; HLA, human leukocyte antigen; Ig,
immunoglobulin; i.v., intravenously; kDa, kilo Dalton; MAGE, melanoma-associated
n; Mda-7, melanoma entiation-associated gene-7; MHC, major
histocompatibility complex; MHC-p, MHC-peptide; NS1, parvovirus-H1 derived non-
structural protein 1; PBSM, PBS containing 2% non-fat dry milk; TCR, T-cell receptor;
VH, Vh or VH, amino-acid sequence of an globulin variable heavy ; Vl,
amino-acid sequence of an immunoglobulin variable light domain; TRAIL, tumor
necrosis factor-related apoptosis-inducing ligand.
Examples.
EXAMPLE 1
Non-exhaustive examples of immunoglobulins of the invention sing at least an
immunoglobulin variable region that specifically binds to an MHC-peptide complex
preferentially associated with aberrant cells or to an aberrant cell surface marker
preferentially associated with nt cells, with domain gies as outlined for
e in Figure 5B, are:
Antibodies of the invention comprising immunoglobulin variable regions that
specifically bind to
a. a complex comprising a T-cell epitope selected from 146-KLQCVDLHV-154
[SEQ-ID 74], 141-FLTPKKLQCV-150 [SEQ-ID 75], 154-VISNDVCAQV-163
D 76], 154-YISNDVCAQV-163 [SEQ-ID 77] of PSA, presented by
HLA-A2 and/or 162-QVHPQKVTK-170 [SEQ-ID 78] of PSA, presented by
HLA-A3, and/or 152-CYASGWGSI-160 [SEQ-ID 79], 248-HYRKWIKDTI-
257 D 80] of PSA, presented by HLA-A24, and/or 4-LLHETDSAV-12
[SEQ-ID 81], 711-ALFDIESKV-719 [SEQ-ID 82], 27-VLAGGFFLL-35 [SEQID
83] of PSMA, presented by HLA-A2, and/or 178-NYARTEDFF-186 [SEQID
84], 227-LYSDPADYF-235 [SEQ-ID 85], 624-TYSVSFDSL-632 [SEQ-ID
86] of PSMA, presented by HLA-A24, and/or 299-ALDVYNGLL-307 [SEQID
87] of PAP, presented by HLA-A2 and/or 213-LYCESVHNF-221 [SEQ-ID
88] of PAP, presented by HLA-A24 and/or 199-GQDLFGIWSKVYDPL-213
[SEQ-ID 89], 228-TEDTMTKLRELSELS-242 D 90] of PAP, presented
by MHC-2 and/or 14-ALQPGTALL-22 [SEQ-ID 91], 105-AILALLPAL-113
[SEQ-ID 92], 7-ALLMAGLAL-15 D 93], YSCKAQV-30
[SEQ-ID 94] of PSCA, presented by HLA-A2 and/or 155-
LLANGRMPTVLQCVN-169 [SEQ-ID 95] of Kallikrein 4, presented by
DRB1*0404 and/or 160-RMPTVLQCVNVSVVS-174 [SEQ-ID 96] of
Kallikrein 4, presented by DRB1*0701 and/or 125-SVSESDTIRSISIAS-139
[SEQ-ID 97] of Kallikerein 4, presented by DPB1*0401, for the treatment of
prostate cancer;
b. the HLA B8 restricted epitope from EBV nuclear n 3, FLRGRAYGL
[SEQ-ID 98], complexed with MHC I, for the clearance of EBV infected cells;
c. the MAGE-A peptide YLEYRQVPG ted by MHC 1 HLA-A0201, for
treatment of cancers accompanied by tumor cells expressing these MHC-peptide
complexes (see Table 1);
d. the MAGE-A peptide EGDCAPEEK presented by MHC-1 HLA-CW7, for
treatment of cancers accompanied by tumor cells expressing these MHC-peptide
complexes (see Table 1);
e. complexes of HLA-A2 and HLA-A2 restricted CD8+ T-cell epitopes, e.g.
nonamer peptides FLFLLFFWL [SEQ-ID 99] (from tic acid phosphatase
(PAP, also prostatic specific acid phosphatase (PSAP))), TLMSAMTNL [SEQID
100] (from PAP), ALDVYNGLL [SEQ-ID 101] (from PAP), human HLA-
A2.1-restricted CTL epitope ILLWQPIPV [SEQ-ID 102] (from PAP-3), sixtransmembrane
lial antigen of prostate (STEAP), or complexes of HLAA2.1
and HLA-A2.1-restricted CTL epitope LLLGTIHAL [SEQ-ID 103] (from
STEAP-3), epitopes from mucin (MUC-1 and MUC-2), 32mer
SAPDTRPAPGSTAPPAHGVTSAPDTRPA [SEQ-ID 104]), epitopes
from Globo H, , Tn(c), TF(c) clusters, GM2, prostate-specific membrane
antigen , kallikrein 4, prostein, or complexes of HLA-A2.1 and HLAA2.1-restricted
epitopes from BA46, PTH-rP, HER-2/neu, hTERT, and MAGEA8
, for the treatment of prostate cancer;
f. an aberrant cell specific epitope in aberrant cell-specific altered MUC-1
complexed with MHC, or to an aberrant cell specific epitope in aberrant cellspecific
altered MUC-1 for, the ing of aberrant cells in for example breast
cancer or for the treatment of colorectal cancer;
g. an aberrant cell specific epitope of the aberrant-cell specific epidermal growth
factor receptor mutant form vIII xed with MHC, or to an nt cell
specific epitope of the epidermal growth factor receptor mutant form vIII, for the
ent of the brain neoplasm glioblastoma multiforme;
h. the complex of MHC with T-cell epitope peptide 369–376 from human Her-
2/neu, for the treatment of malignancies related to Her-2 and/or Her-1 overexpression
i. an epitope of the aberrant-cell specific surface marker CD44 splice variants
known as CD44-v6, CD44-v9, CD44-v10, complexed with MHC, or to an
aberrant cell specific epitope of an aberrant-cell specific CD44 splice variant,
for the treatment of le myeloma;
Target binding sites suitable for specific and selective targeting of infected aberrant cells
by antibodies of the invention are pathogen-derived antigen peptides xed with
MHC molecules. Examples of T-cell epitopes of the E6 and E7 protein of human
papilloma virus, complexed with indicated HLA molecules, are provided below. Any
combination of an HLA molecule complexed with a pathogen-derived T-cell epitope
provides a specific target on infected aberrant cells for antibodies of the invention. An
example of an ed aberrant cell is a nocyte in the cervix infected by human
oma virus (HPV), presenting T-cell es derived from for example E6 or E7
protein, in the context of MHC. Examples of suitable target HPV 16 E6 T-cell epitopes
are peptides FQDPQERPR [SEQ-ID 39], TTLEQQYNK [SEQ-ID 40], YCYS
[SEQ-ID 41] and GTTLEQQYNK [SEQ-ID 42] binding to HLA A1, KISEYRHYC
[SEQ-ID 43] and GTTL [SEQ-ID 44] binding to HLA A2, LLRREVYDF
[SEQ-ID 45] and NPY [SEQ-ID 46] binding to HLA A3, TTLEQQYNK
[SEQ-ID 47] g to HLA A11, CYSLYGTTL [SEQ-ID 48], KLPQLCTEL [SEQID
49], HYCYSLYGT [SEQ-ID 50], LYGTTLEQQY [SEQ-ID 51], EVYDFAFRDL
[SEQ-ID 52] and VYDFAFRDLC [SEQ-ID 53] binding to HLA A24, 29-
LECV-38 D 54] binding to HLA A*0201. Equally suitable are HPV 16
E7 T-cell es such as 86-TLGIVCPI-93 [SEQ-ID 55], 82-LLMGTLGIV-90 [SEQID
56], 85-GTLGIVCPI-93 [SEQ-ID 57] and 86-TLGIVCPIC-94 [SEQ-ID 58] binding
to HLA A*0201, HPV 18 E6 T-cell epitopes and HPV 18 E7 T-cell epitopes, binding to
HLA A1, A2, A3, A11 or A24. Yet additional examples of T-cell epitopes related to
HPV infected cells are HPV E7 derived peptides 1-MHGDTPTLHEYD-12 [SEQ-ID 59],
48-DRAHYNIVTFCCKCD-62 D 60] and 62-DSTLRLCVQSTHVD-75 [SEQID
61] binding to HLA DR, 7-TLHEYMLDL-15 [SEQ-ID 62], 11-YMLDLQPETT-20
[SEQ-ID 63], 11-YMLDLQPET-19 [SEQ-ID 64] and 12-MLDLQPETT-20 [SEQ-ID
65] binding to HLA A*201, 16-QPETTDLYCY-25 [SEQ-ID 66], 44-QAEPDRAHY-52
[SEQ-ID 67] and 46-EPDRAHYNIV-55 [SEQ-ID 68] g to HLA B18, 35-
EDEIDGPAGQAEPDRA-50 [SEQ-ID 69] binding to HLA DQ2, 43-
GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR-77 [SEQ-ID 70] binding to
HLA DR3, 50-AHYNIVTFCCKCD-62 [SEQ-ID 71] binding to HLA DR15, 58-
CCKCDSTLRLC-68 [SEQ-ID 72] binding to HLA DR17 and 61-
LCVQSTHVDIRTLE-80 [SEQ-ID 73] binding to HLA-DRB1*0901.
A good source for selecting binding sites suitable for specific and selective targeting of
nt cells by antibodies of the ion, is the Peptide Database listing T-cell
defined tumor antigens and the HLA’s g the T-cell epitopes [9-12;
www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm]. The database provides
combinations of antigen peptides complexed with MHC molecules comprising the
indicated class of HLA, unique to tumor cells or over-expressed by tumor cells.
EXAMPLE 2: Selection of human antibody fragments specific for HLAA0201
/multi-MAGE-A.
To obtain human antibody fragments comprising immunoglobulin variable regions
specific for the HLA-A0201 presented multi-MAGE-A epitope Y-L-E-Y-R-Q-V-P-V
D 6] and ALV [SEQ-ID 23] a Human Fab phage display library was
constructed according to the procedure previously described by de Haard et al (2) and
used for selections 1) essentially as described by Chames et al using biotinilated MHC/p
complexes (3), or 2) on cells expressing the nt antigen.
2.1: selection of human antibody fragments specific for HLA-A0201/YLEYRQVPV using
biotinilated MHC-peptide xes:
Human Fab phages (1013 colony forming units) were first pre-incubated for 1 h at room
temperature in PBS ning 2% non-fat dry milk (PBSM). In parallel, 200 l
Streptavidin-coated beads (Dynal™) were equilibrated for 1 h in PBSM. For subsequent
rounds, 100 l beads were used. To deplete for pan-MHC s, each selection round,
200 nM of biotinylated MHC class I-peptide ) complexes containing an
irrelevant peptide (Sanquin, the Netherlands) were added to the phages and incubated for
minutes under rotation. Equilibrated beads were added, and the mixture was incubated
for 15 minutes under on. Beads were drawn to the side of the tube using magnetic
force. To the depleted phage fraction, subsequently decreasing amounts of biotinylated
MHC-p complexes (200 nM for the first round, and 20 nM for the second and third round)
were added and incubated for 1 h at room temperature, with continuous on.
Simultaneously, a pan-MHC class I binding soluble Fab (D3) was added to the phage-
MHC-p complex mixture (50, 10, and 5 µg for rounds 1-3 respectively). Equilibrated
streptavidin-coated beads were added, and the mixture was incubated for 15 minutes
under rotation. Phages were selected by magnetic force. Non-bound phages were
d by 5 washing steps with PBSM, 5 steps with PBS containing 0.1% Tween, and
steps with PBS. Phages were eluted from the beads by 10 minutes incubation with 500
l freshly prepared tri-ethylamine (100 mM). The pH of the solution was lized by
the on of 500 l 1 M Tris (pH 7.5). The eluted phages were incubated with
logarithmic growing E. Coli TG1 cells (OD600nm of 0.5) for 30 minutes at 37C. Bacteria
were grown overnight on 2x TYAG plates. Next day, colonies were harvested, and a 10
l inoculum was used in 50 ml 2x TYAG. Cells were grown until an OD600nm of 0.5, and
5 ml of this suspension was infected with M13k07 helper phage (5x1011 colony forming
units). After 30 minutes incubation at 37C, the cells were centrifuged, resuspended in
ml 2x TYAK, and grown overnight at 30C. Phages were collected from the culture
supernatant as described previously, and were used for the next round panning. After
three selection rounds a 261-fold enrichment was obtained, and 46 out of 282 analyzed
clones were shown to be specific for the HLA-A2-multi-MAGE-A x (Figure 1).
ELISA using the HLA-A0201/multi-MAGE-A complexes as well as HLA-A0201
complexes with a peptide d from JC virus was used to ine the specificity of
the selected Fab.
2.2: Selection of human Fab specific for HLA-A0201/FLWGPRALV using cells.
Selections of Fab-phages specifically binding to HLA-A0201/FLWGPRALV were performed
using mouse CMT64 lung tumor cells. To obtain CMT64 cells stably expressing HLAA0201
/FLWGPRALV (A2/FLW) complexes, the CMT64 cells were retroviral infected with a
vector encoding a single chain e-?2M-HLA-A0201 heavy chain construct [SEQ ID 105].
Human Fab phages (1013 colony forming units) were first cubated for 1 h at room
temperature in PBS containing 2% FCS (PBSF). In parallel, 6 CMT64-A2/FLW cells were
equilibrated for 1 h in PBSF. The phages were first incubated for one hour with 10x106 CMT 64
cells expressing HLA-A0210/ YLEYRQVPG to deplete non-specifically binding phages. The
und fraction was then incubated (1 hr at 4oC) with HLA-A0201/FLWGPRALV
sing CMT64 cells. After extensive washing, bound phages were eluted by adding 500 l
freshly prepared tri-ethylamine (100 mM). The pH of the solution was lized by the addition
of 500 l 1 M Tris (pH 7.5). The eluted phages were incubated with logarithmic growing E. Coli
TG1 cells (OD600nm of 0.5) for 30 minutes at 37C. Bacteria were grown overnight on 2x TYAG
plates. Next day, colonies were ted. After four rounds of selection individual clones were
selected and tested for specificity of binding.
2.3: Human Fab ic for HLA-A0201/multi-MAGE-A epitopes bind antigen
ve cells.
Multi-MAGE-A; Y-L-E-Y-R-Q-V-P-V
Fab phages were analyzed for their capacity to bind HLA-A0201 positive EBV-
transformed B-LCL loaded with the multi-MAGE-A peptide Y-L-E-Y-R-Q-V-P-V. The
B-LCL line BSM (0.5x106) was loaded with multi-MAGE-A peptide (10 g in 100 l
PBS) for 30 minutes at 37C, followed by incubation with the Fab phages AH5, CB1,
CG1, BD5 and BC7 and analyzed by flow-cytometry. As shown in Figure 2, Fab AH5,
CB1 and CG1, specifically bound to the peptide loaded cells only, whereas Fab BD5 and
BC7 displayed non-specific binding to BSM that was not loaded with the multi-MAGEA
peptide. No binding was observed by AH5, CB1 and CG1 to non-peptide loaded cells.
Phages presenting AH5, CB1 and CG1, as well as the HLA-A0101/MAGE-A1 specific
Fab phage G8 (4) were then used to stain tumor cell lines of distinct histologic origin. To
this end prostate cancer cells (LNCaP), multiple myeloma cells (MDN), melanoma cells
(MZ2-MEL43 and G43), and breast cancer cells (MDA-MB157) were stained and
analyzed by flow cytometry e 3). The Fab AH5 specifically bound multiple
myeloma cells MDN, and not the HLA-A0201 negative melanoma and breast cancer
cells. Both CB1 and CG1 displayed non-specific binding on the melanoma cell line G43.
The positive control Fab G8 demonstrated binding to all cell lines tested.
Multi-MAGE-A: F-L-W-G-P-R-A-L-V
To determine the inding capacity of the HLA-A0201/ FLWGPRALV ed Fab clone
F9 soluble Fab fragments were made by induction of TG-1 ia. TG-1 containing pCes-F9
were grown until OD=0,8 and Fab production was induced by addition of 1 mM IPTG. After 13
hours induction the bacterial periplasmic on was isolated and dialyzed overnight. Next day
soluble Fab F9 fragments were purified by IMAC.
Purified Fab F9 was added to 0,5x106 CMT 64 cells expressing either HLA-A0210/
YLEYRQVPG, HLA-A0201/ FLWGPRALV, or CMT 64 cells that do not express human HLA.
As shown in Figure 6 the Fab clone F9 specifically binds HLA-A0201/ ALV
expressing CMT64 cells and not CMT 64 cells that do not express human HLA or that do s
the irrelevant HLA-A0201/ YLEYRQVPG molecules.
2.4: Fab AH5 binds HLA-A0201/multi-MAGE-A xes only.
ELISA using multiple peptide/MHC complexes then confirmed the specificity of Fab-
AH5. To this end HLA-A0201 complexes presenting peptides multi-MAGE-A, gp100,
JCV and MAGE-C2, as well as a HLA-A1/MAGE-A1 complex were immobilized on 96
well plates and ted with phages displaying Fab AH5 and control Fab G8. As shown
in Figure 4, AH5 only binds HLA-A0201/multi-MAGE-A and not the vant
complexes HLA-A0201/gp100, HLA-A0201/MAGE-C2, HLA-A0201/JCV and HLAA0101
/MAGE-A1. The positive control Fab G8 only binds to its relevant target HLAA0101
/MAGE-A1.
The nucleic acids ng for the HLA-A0201 – multi-MAGE-A complex binding Fab
AH5 will be combined with nucleic acids encoding for human antibody Ch2-Ch3
domains, providing nucleic acid molecules encoding for a human antibody light chain
encompassing the selected Cl-Vl encoding nucleic acids and encoding for a human
antibody heavy chain encompassing the selected Ch-Vh encoding nucleic acids. These
nucleic acid molecules encoding the desired immunoglobulin will be introduced, via a
d or via an expression vector, into a eukaryotic host cell such as a CHO cell. After
expression of the immunoglobulin, it will be isolated from the cell culture and ed.
Then, a selected toxic moiety will be linked to the immunoglobulin, for example using
Universal Linkage System linker chemistry.
Example 3. Cell binding and internalization of an immunoglobulin provided with a
toxic moiety.
g capacity of an antibody of the invention is analyzed by flow-cytometry. For
example, an antibody comprising immunoglobulin variable regions specific for
complexes of HLA-A0201 and the multi-MAGE-A peptide is analysed. HLA-
A0201/multi-MAGE-A positive tumor cells (Daju, MDN and mel 624) and HLAA0201
/multi-MAGE-A negative cells (BSM, G43 and 293) are incubated on ice with
purified antibody and ed by addition of fluorescently labeled antibodies. Cells
bound by the antibody are quantified and visualized by ytometry. Internalisation
of antibody is ed by confocal microscopy. To this end cells are incubated with the
antibody, kept on ice for 30 minutes to allow binding but no internalization. Next,
fluorescently labeled dies specific for the antibody are added. To induce
alization cells are transferred to 37oC and fixed with 1% PFA after 5, 10 and 15
minutes.
Example 4: Apoptosis induction by antibodies of the invention in e tumor
cells.
4.1: killing of diverse tumor cells by immunoglobulin provided with a toxic
moiety.
Antibodies of the ion are analyzed for their capacity to induce sis by
incubation with diverse tumor cells, known to express the antigens comprising the
binding sites for the immunoglobulin variable regions. For example, an antibody
comprising immunoglobulin variable region VH specific for complexes of HLA-A0201
and the multi-MAGE-A peptide, AH5-BTX, is coupled to a synthetic HPMA polymer
containing the BTX peptide and bicin (as we described in WO2009131435) and
analyzed. To this end antibodies of the invention coupled to doxorubicin are analyzed
for their capacity to induce apoptosis by incubation with e tumor cells known to
express both HLA-A0201 and MAGE-A genes. The cell-lines Daju, Mel 624
(melanoma), PC346C (prostate cancer), and MDN (multiple myeloma) as well as
MAGE-A negative cells (911 and HEK293T) are incubated with different concentrations
of the antibodies of the invention (in DMEM medium, supplemented with pen/strep,
Glutamine and non-essential amino acids). Several hours later, cells are visually
inspected for classical signs of apoptosis such as detachment of the cells from tissue
culture plates and membrane blebbing. In addition, cells are stained for active caspase-3
to demonstrate sis. It is excepted that the antibodies of the invention induce
apoptosis in the Daju Mel 624, PC346C and MDN cells. Cells that are not treated with
the antibodies of the ion are not affected, as well as cells that do not express 01
(HEK293T) and MAGE-A genes (911 and HEK293T).
Another antibody, comprising Vh and Vl domains (scFv) with specificity for complexes
of HLA-A01, presenting a MAGE-A1 peptide was also analyzed. The scFv-BTX
construct was coupled to the HPMA polymer containing doxorubicin and incubated with
MAGE-A1 positive and MAGE-A1 negative cells. sis is shown by staining for
active caspase-3.
4.2: ion of active caspase-3.
A classical intra-cellular hallmark for sis is the presence of active caspase-3. To
determine r or not the antibodies of the invention induce active caspase-3, Daju,
Mel624 and MDN cells are incubated with s concentrations of antibodies of the
invention. After four and 13 hours FAM –DEVD-FMK, a fluorescently caspase-3/7
inhibitor, is added and positively stained cells are visualized by scent microscopy
and flow-cytometry. e-3 activity is shown in antigen positive cells and not in
antigen negative cells, with the (fragment of the) antigen providing the specific -
g site for the antibodies of the invention.
4.3 Treatment of tumor bearing mice with immunoglobulins provided with a toxic
Nude mice (NOD-scid, 8 per group) with a palpable subcutaneous transplantable human
tumor (Daju or MDN) are injected with different doses of immunoglobulins provided
with a toxic moiety. As a control mice are treated with standard chemotherapy or receive
an injection with PBS. Mice receiving an optimal dose of the immunoglobulins provided
with a toxic moiety survive significantly longer that those mice receiving chemotherapy
or PBS, when the aberrant cells expose the target binding sites for the antibodies of the
invention.
Example 5: ion of llama VHH with specificity for HLA-A0201/ ALV and
HLA-A0201/ YLEYRQVPG.
Selection of Llama VHH fragments with specificity for 201/ ALV (A2/FLW)
and HLA-A0201/YLEYRQVPG (A2/YLE) were performed on CMT64 cells stably expressing
these HLA/peptide complexes. Llama VHH phages (1011 colony forming units) were first preincubated
for 1 h at room temperature in PBS containing 2% FCS (PBSF). In parallel, 1.0x106
CMT64-A2/FLW and 1.0x106 CMT64 A2/YLE cells were equilibrated for 1 h in PBSF. To
deplete for non-specific binding phages 10x106 CMT 64 cells expressing either A2/FLW or
A2/YLE were incubated for one hour with the llama VHH. The non-bound fractions were then
incubated (1 hr at 4oC) with A2/FLW or A2/YLE sing CMT64 cells. After extensive
washing, bound phages were eluted by adding 500 l y ed tri-ethylamine (100 mM).
The pH of the solution was neutralized by the addition of 500 l 1 M Tris (pH 7.5). The eluted
phages were incubated with logarithmic growing E. Coli TG1 cells (OD600nm of 0.5) for 30
s at 37C. Bacteria were grown overnight on 2x TYAG plates. Next day, colonies were
harvested. After four rounds of selection individual clones were selected and tested for specificity
of binding.
.2: Llama VHH specific for HLA-A0201/multi-MAGE-A epitopes bind antigen positive
cells.
To determine the cell-binding capacity of the A2/FLW and A2/YLE selected VHH soluble VHH
fragments were made by ion of TG-1 bacteria. TG-1 containing HH were grown
until OD=0,8 and Fab production was induced by addition of 1 mM IPTG. After 13 hours
induction the ial periplasmic fraction was isolated and ed overnight. Next day
soluble VHH fragments were ed by IMAC.
CMT 64 cells (0,5x106) expressing either HLA-A0210/ YLEYRQVPG, HLA-A0201/
FLWGPRALV, or CMT 64 cells that do not express human HLA were incubated with purified
VHH fragments for one hour at 4oC. As shown in Figure 7 the A2/FLW specific VHH bind HLAA0201
/ FLWGPRALV expressing CMT64 cells and not CMT 64 cells that do not express
human HLA or that do express the irrelevant HLA-A0201/ YLEYRQVPG molecules. The
A2/YLE specific VHH only bind HLA-A2/YLEYRQVPG expressing CMT64 cells and not
A2/FLW positive CMT64 cells and CMT64 cells that do not express human HLA.
References
1. Stephanie Graff-Dubois, Olivier Faure, David-Alexandre Gross, Pedro
Alves,Antonio Scardino, Salem b, Francois A. Lemonnier and Kostas
Kosmatopoulos. tion of CTL Recognizing an HLA-A*0201-Restricted
Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens:
Implication in a Broad-Spectrum Tumor Immunotherapy. The Journal of
Immunology, 2002, 169: 575–580.
2. Hans J. de Haard, Nicole van Neer, Anneke Reurs, Simon E. Hufton, Rob C. Roovers,
Paula Henderikx, Adriaan P. de , Jan-Willem Arends, and Hennie R.
Hoogenboom. A Large Non-immunized Human Fab Fragment Phage Library That
Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies. The
Journal of Biological Chemistry. 1999, 274: 18218 –18230.
3. Chames P, Hoogenboom H.R, Henderikx P. Selection of antigens against
ylated antigens. In Antibody phage display, methods and protocols, Edited by
P.M. O’Brien and R. Aitken. Methods in Molecular Biology 2002, 178:147-159.
4. Patrick Chames, Simon E. Hufton, Pierre G. Coulie, Barbara Uchanska-Ziegler,
Hennie R. boom. Direct selection of a human antibody fragment directed
against the tumor T-cell e HLA-A1–MAGE-A1 from a nonimmunized phage-
Fab library. PNAS, 2000. 97: 7969 –7974.
5. H.M. rn, ns selectively killing tumor cells. Eur. J. Pharmacol., 2009.
625: 165-173.
6. r, B.A. & Chari, R.V.J., Antibody conjugate therapeutics: challenges and
potential. Clin. Cancer Res., 2011, 17(20):6389-97.
7. McCurdy DK, Tai LQ, Imfeld KL, Schwartz M, Zaldivar F, Berman MA, Expression
of melanoma antigen gene by cells from inflamed joints in juvenile rheumatoid
tis, J. tol. 2002, 29:2219-2224.
8. Marcar L, Maclaine NJ, Hupp TR, Meek DW, Mage-A cancer/testis antigens t
p53 function by blocking its interaction with chromatin, Cancer Res. 2010, 70:10362-
10370.
9. Van den Eynde B.J., van der Bruggen P., T cell-defined tumor antigens. Curr. Opin.
Immunol. 1997; 9: 684-93.
. Houghton A.N., Gold J.S., Blachere N.E., Immunity against cancer: lessons learned
from melanoma. Curr. Opin. Immunol. 2001; 13: 134-40.
11. van der Bruggen P., Zhang Y., Chaux P., Stroobant V., Panichelli C., Schultz E.S.,
Chapiro J., Van den Eynde B.J., Brasseur F., Boon T., Tumor-specific shared
antigenic peptides recognized by human T cells. l. Rev. 2002; 188: 51-64.
12. Parmiani G., De Filippo A., Novellino L., li C., Unique human tumor
antigens: immunobiology and use in clinical trials. J. Immunol. 2007; 178: 1975-9.
13. Renkvist, N., Castelli, C., Robbins, P.F., Parmiani, G., A listing of human tumor
antigens ized by T-cells, Cancer Immunol. Immunother. 2001; 50: 3-15.
14. Ridgway, J.B.B., Presta, L.G., Carter, P., -into-holes' engineering of
antibody CH3 domains for heavy chain heterodimerization Protein Engineering,
1996; 9, no.7: 617-621.
Table 1: Examples of the frequency of MAGE-A expression by human cancers.
Frequency of expression (%)
Cancer MAG MAG MAG MAG MAG MAG MAG
E-A1 E-A2 E-A3 E-A4 E-A6 E-A10 E-A11
ma 16 E 36 E 64 E 74
Head and neck 25 42 33 8 N N N
Bladder 21 30 35 33 15 N 9
Breast 6 19 10 13 5 N N
Colorectal N 5 5 N 5 N N
Lung 21 30 46 11 8 N N
Gastric 30 22 57 N N N N
Ovarian 55 32 20 E 20 N N
Osteosarcoma 62 75 62 12 62 N N
hepatocarcino 68 30 68 N 30 30 30
Renal cell 22 16 76 30 N N N
carcinoma
E, expressed but the frequency is not known; N, expression by tumors has never been
observed
Table 2: MAGE-A expression in human te cancer cell lines and prostate
cancer xenografts.
MAGECell
line / A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12
Xenograft
LNCaP + ++ ++ ++ +
PC346C + ++ ++ + ++ + + ++
OVCAR + + + +
JON ++ ++ ++ + +
PNT 2 C2 + + + + +
SD48 + + + +
PC-3 + + +
PC 374 +
PC 346p + ++ ++ ++ + ++ +
PC 82 + +
PC 133 ++ + +
PC 135 +
PC 295 +
PC 324 + + +
PC 310 + ++ + ++ +
PC 339 ++ ++ + ++ + + +
Expression of the MAGE-A1, A2, A3, A4, A5, A6 ,A7, A8, A9, A10, A11 and A12
genes in diverse prostate tumor cell lines and prostate xenografts was ed by RTPCR.
Shown are expression levels in individual samples tested. Blank= no expression,
+ = low expression, ++ = high expression.
All cell lines / xenografts express at least one MAGE-A gene.
Figure legends
Figure 1: Specific g of HLA-A0201/multi-MAGE-A specific phage clones
isolated from a large human non-immune antibody Fab phage library. dual
antibody Fab expressing phages that were selected against biotinylated 01
/multi-MAGE-A were analysed by ELISA for their ty to bind the relevant
peptide/MHC complex only. Streptavidin coated 96 well plates were incubated with
soluble HLA-A0201/multi-MAGE-A (A2/multiMage) or HLA-A0201/JCV (A2/JC)
peptide/MHC complexes (10 µg/ml), washed to remove non-bound complexes and
incubated with individual phage . Non-binding phages were first removed by three
washes with PBS/Tween, ed by incubation with anti-M13 antibody (1 µg/ml,
Amersham) for one hour by room temperature. Finally the wells were incubated with an
HRP-labeled secondary antibody and bound phages detected.
Figure 2: Phages AH5, CB1 and CG1 specifically bind cells presenting the multi-
MAGE-A peptide. Phages AH5, CB1, CG1, BD5 and BC7 that had shown specific
binding in ELISA using the relevant HLA-A201/multi-MAGE-A complex and an
irrelevant HLA-A201 complex loaded with a JCV peptide were analysed for their
capacity to bind cells presenting the MAGE-A peptide in HLA-A0201 molecules.
To this end, human B-LCL (BSM) were loaded with MAGE-A peptide (10 g in
100 l PBS) for 30 s at 37C, ed by incubation with the Fab phages AH5,
CB1, CG1, BD5 and BC7 and analyzed by flow-cytometry using anti-phage antibodies
and a fluorescently labeled secondary antibody.
Figure 3: Phages expressing HLA-A2/multi-MAGE-A specific Fab bind tumor cells
of distinct histologic origin. Phages AH5, CB1 and CG1 specific for HLAA0201
/multi-MAGE-A and a positive control phage specific for HA-0101/MAGE-A1
were used for staining of distinct tumor cell lines. To this end the prostate cancer cell line
LNCaP, the multiple myeloma cell line MDN, the melanoma cell lines L43 and
G43, and the breast cancer cell line MDA-MD157 were incubated with the different
phages (30 minutes at 4C), bound phages were then detected by flow cytometry using
anti-phage antibodies and fluorescently labeled secondary antibodies.
Figure 4: Phage AH5 specifically binds HLA-A0201/multi-MAGE-A complexes
only. To determine specificity of the phage AH5 an ELISA was performed using relevant
and irrelevant e/MHC complexes. HLA-A0201 with multi-MAGE-A, gp100, JCV
and MAGE-C2 peptides, as well as HLA-A1 with 1 peptide were coated on
streptavidin 96 well plates and incubated with phage AH5.
Figure 5: Cartoon displaying examples of preferred immunoglobulins provided
with a toxic moiety, according to the invention.
A. Cartoon displaying the topology of the twelve immunoglobulin domains assembled
in an immunoglobulin G. B. Examples are provided of preferred immunoglobulins
provided with a toxic moiety, according to the invention in which
I. is an IgG provided with a chemically linked toxic moiety and comprising a
variable region specific for a e derived from an intracellular tumor-specific
protein and presented at the tumor cell surface in the context of MHC.
II. is a bi-specific IgG provided with a chemically linked toxic moiety and
comprising two different variable regions specific for one or two peptides derived
from one or two intracellular tumor-specific protein(s) and presented at the tumor
cell surface in the context of MHC.
III. is an IgG provided with a toxic moiety linked through a peptide linker
ated via peptide bonds, and sing a variable region specific for peptide
derived from an intracellular tumor-specific protein and presented at the tumor cell
e in the context of MHC.
IV is a bispecific IgG provided with one heavy chain comprising a toxic moiety
linked through a peptide linker integrated by peptide bonds, and comprising two
different variable regions ic for one or two es derived from one or two
intracellular tumor-specific proteins(s) and presented at the tumor cell surface in
the context of MHC.
Thus shown are globulins provided with a single toxic moiety such as for
example a cytostatic agent, linked to the immunoglobulin with a chemical linker
(exemplified by I. and II.; immunoglobulin-toxic moiety conjugates), or
immunoglobulins provided with a single toxic moiety, linked to the immunoglobulin
with a peptide linker (exemplified by III.; fused immunoglobulin-toxic moiety
molecule). In IV., an immunoglobulin provided with a toxic , according to the
invention, is shown, comprising one immunoglobulin heavy chain comprising a fused
proteinaceous toxic moiety, comprising globulin variable regions specific for a
certain binding site, and comprising a second immunoglobulin heavy chain comprising
immunoglobulin variable regions specific for a different binding site. Of course, also part
of the invention are bi-specific immunoglobulins provided with a toxic moiety, according
to the invention, comprising two heavy chains comprising different immunoglobulin
variable regions specific for ent binding sites and further comprising the same or
different proteinaceous toxic moieties fused two the heavy chains. Of course, as part of
the invention, more than one, and typically two to six toxic moiety molecules can be
fused or conjugated to an immunoglobulin molecule.
Figure 6: Human Fab phage F9 specifically binds HLA-A2/ FLWGPRALV positive
CMT64 mouse lung tumor cells.
Human Fab clone F9 was analysed for its capacity to bind mouse lung tumor cells (CMT64)
stably expressing the HLA-A2/ ALV complex. Purified Clone F9 Fab fragments (3
g total) were incubated with 0,5x106 CMT64 cells that do not express human HLA, that
s HLA-A2/YLEYRQVPG or that s HLA-A2/ FLWGPRALV. After one hour
tion on ice CMT64 cells were incubated with a scently labeled ary antibody
and analysed by flow cytometry.
Figure 7: Llama VHH specifically binds CMT64 mouse lung tumor cells expressing
human HLA-A2/multi-MAGE-A.
Llama VHH specific for A2/FLW or A2/YLE were analysed by flow cytometry for their
binding capacity to CMT64 cells expressing these human HLA-A0201/multi-MAGE-A
complexes. Purified VHH fragments (3 g total) were ted with 0,5x106 CMT64 cells,
that do not express human HLA, that express HLA-A2/YLEYRQVPG or that express HLAA2
/ FLWGPRALV. After one hour incubation on ice CMT64 cells were incubated with a
fluorescently labeled ary antibody and analysed by flow cytometry.
In Figure 7A, the HLA-A0201/YLEYRQVPG ic nanobody is shown as binding to
CMT64 mouse cells expressing HLA-A0201 with covalently linked YLEYRQVPG MAGE-A
epitope. No binding to CMT64 cells expressing HLA0201 with the FLWGPRALV epitope
was seen.
In Figure 7B, the HLA-A0201/FLWGPRALV ic dy is shown as binding to
CMT64 mouse cells expressing HLA-A0201 with covalently linked FLWGPRALV MAGE-A
epitope. No binding to CMR64 cells expressing HLA0201 with the YLEYRQVPG epitope
was seen.
Sequence identifiers
SEQ-ID 1. Amino acid ce Vh AH5
QLQLQESGGG VVQPGRSLRL SCAASGFTFS VRQA PGKEREGVAV
ISYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAGGS
YYVPDYWGQG TLVTVSSGST SGS
SEQ-ID 3. Amino acid sequence MHC-1 HLA-A0201 table peptide in MAGE-A
YLEYRQVPG
SEQ-ID 4. Amino acid sequence MHC-1 HLA-CW7 presentable e in MAGE-A
EGDCAPEEK
SEQ-ID 5. Amino acid sequence MHC-1 201 presentable peptide in MAGE-
A1
YLEYRQVPD
SEQ-ID 6. Amino acid sequence MHC-1 HLA-A0201 presentable peptide in MAGEA1
, with enhanced binding capacity for HLA-A0201
YLEYRQVPV
SEQ-ID 7. Amino acid sequence Vh binding domain 11H
EVQLVQSGGG LVKPGGSLRL SCAASGFTFS DYYMSWIRQA PGKGLEWLSY
ISSDGSTIYY ADSVKGRFTV SRDNAKNSLS LQMNSLRADD TAVYYCAVSP
RGYYYYGLDL WGQGTTVTVS S
SEQ-ID 8, amino acid sequence of MAGE-A3 peptide epitope binding to HLA
IMPKAGLLI
SEQ-ID 9, amino acid sequence of MAGE-A3 peptide epitope g to HLA
KKLLTQHFVQENYLEY
SEQ-ID 10, amino acid sequence of MAGE peptide epitope binding to HLA
EADPTGHSY
SEQ-ID 11, amino acid ce of MAGE peptide epitope binding to HLA
SLFRAVITK
SEQ-ID 12, amino acid sequence of MAGE peptide epitope binding to HLA
NYKHCFPEI
SEQ-ID 13, amino acid sequence of MAGE peptide epitope binding to HLA
EVYDGREHSA
SEQ-ID 14, amino acid sequence of MAGE e epitope binding to HLA
REPVTKAEML
SEQ-ID 15, amino acid sequence of MAGE peptide e binding to HLA
DPARYEFLW
SEQ-ID 16 amino acid sequence of MAGE peptide epitope binding to HLA
SAFPTTINF
SEQ-ID 17, amino acid sequence of MAGE peptide e binding to HLA
SAYGEPRKL
SEQ-ID 18, amino acid ce of MAGE peptide epitope binding to HLA
SAYGEPRKL
SEQ-ID 19, amino acid sequence of MAGE peptide epitope binding to HLA
KMVELVHFL
SEQ-ID 20, amino acid sequence of MAGE peptide epitope binding to HLA
YLQLVFGIEV
SEQ-ID 21, amino acid sequence of MAGE peptide epitope binding to HLA
EYLQLVFGI
SEQ-ID 22, amino acid sequence of MAGE peptide epitope binding to HLA
EADPIGHLY
SEQ-ID 23, amino acid sequence of MAGE peptide epitope binding to HLA
FLWGPRALV
SEQ-ID 24, amino acid ce of MAGE e epitope binding to HLA
MEVDPIGHLY
SEQ-ID 25, amino acid sequence of MAGE peptide epitope binding to HLA
WQYFFPVIF
SEQ-ID 26, amino acid sequence of MAGE peptide epitope binding to HLA
GVYDGREHTV
SEQ-ID 27, amino acid ce of MAGE peptide epitope binding to HLA
MVKISGGPR
SEQ-ID 28, amino acid sequence of MAGE e epitope binding to HLA
GLYDGMEHL
SEQ-ID 29, amino acid sequence of MAGE peptide epitope binding to HLA
VRIGHLYIL
SEQ-ID 30, amino acid sequence of BAGE peptide e binding to HLA
AARAVFLAL
SEQ-ID 31, amino acid sequence of DAM-6 and DAM-10 peptide epitope binding to
FLWGPRAYA
SEQ-ID 32, amino acid sequence of /-2/-8 peptide epitope binding to HLA
YRPRPRRY
SEQ-ID 33, amino acid sequence of GAGE-3/-4/-5/-6/-7B peptide epitope binding to
HLA
YYWPRPRRY
SEQ-ID 34, amino acid sequence of NA88-A peptide epitope binding to HLA
MTQGQHFLQKV
SEQ-ID 35, amino acid sequence of NY-ESO-1 e epitope binding to HLA
TQCFL
SEQ-ID 36, amino acid sequence of -1a peptide epitope binding to HLA
SLLMWITQC
SEQ-ID 37, amino acid sequence of NY-ESO-1a peptide epitope binding to HLA
QLSLLMWIT
SEQ-ID 38, amino acid ce of NY-ESO-1a peptide epitope binding to HLA
ASGPGGGAPR
SEQ-ID 39, HPV 16 E6 T-cell epitope binding to HLA A1
FQDPQERPR
SEQ-ID 40, HPV 16 E6 T-cell epitope binding to HLA A1
TTLEQQYNK
SEQ-ID 41, HPV 16 E6 T-cell epitope binding to HLA A1
ISEYRHYCYS
SEQ-ID 42, HPV 16 E6 T-cell epitope binding to HLA A1
GTTLEQQYNK
SEQ-ID 43, HPV 16 E6 T-cell epitope binding to HLA A2
KISEYRHYC
SEQ-ID 44, HPV 16 E6 T-cell epitope binding to HLA A2
YCYSIYGTTL
SEQ-ID 45, HPV 16 E6 T-cell epitope g to HLA A3
LLRREVYDF
SEQ-ID 46, HPV 16 E6 T-cell epitope binding to HLA A3
IVYRDGNPY
SEQ-ID 47, HPV 16 E6 T-cell epitope binding to HLA A11
TTLEQQYNK
SEQ-ID 48, HPV 16 E6 T-cell epitope binding to HLA A24
CYSLYGTTL
SEQ-ID 49, HPV 16 E6 T-cell epitope binding to HLA A24
KLPQLCTEL
SEQ-ID 50, HPV 16 E6 T-cell epitope binding to HLA A24
HYCYSLYGT
SEQ-ID 51, HPV 16 E6 T-cell epitope binding to HLA A24
EQQY
SEQ-ID 52, HPV 16 E6 T-cell epitope binding to HLA A24
EVYDFAFRDL
SEQ-ID 53, HPV 16 E6 T-cell epitope g to HLA A24
VYDFAFRDLC
SEQ-ID 54, HPV 16 E6 T-cell epitope binding to HLA A*0201
29-TIHDIILECV-38
SEQ-ID 55, HPV 16 E7 T-cell epitope binding to HLA A*0201
86-TLGIVCPI-93
SEQ-ID 56, HPV 16 E7 T-cell epitope binding to HLA A*0201
82-LLMGTLGIV-90
SEQ-ID 57, HPV 16 E7 T-cell epitope binding to HLA A*0201
85-GTLGIVCPI-93
SEQ-ID 58, HPV 16 E7 T-cell epitope binding to HLA A*0201
86-TLGIVCPIC-94
SEQ-ID 59, HPV E7 T-cell epitope binding to HLA DR
1-MHGDTPTLHEYD-12
SEQ-ID 60, HPV E7 T-cell epitope binding to HLA DR
48-DRAHYNIVTFCCKCD-62
SEQ-ID 61, HPV E7 T-cell epitope g to HLA DR
LRLCVQSTHVD-75
SEQ-ID 62, HPV E7 T-cell e binding to HLA A*201
7-TLHEYMLDL-15
SEQ-ID 63, HPV E7 T-cell epitope binding to HLA A*201
11-YMLDLQPETT-20
SEQ-ID 64, HPV E7 T-cell epitope binding to HLA A*201
11-YMLDLQPET-19
SEQ-ID 65, HPV E7 T-cell epitope binding to HLA A*201
12-MLDLQPETT-20
SEQ-ID 66, HPV E7 T-cell epitope binding to HLA B18
16-QPETTDLYCY-25
SEQ-ID 67, HPV E7 T-cell epitope binding to HLA B18
44-QAEPDRAHY-52
SEQ-ID 68, HPV E7 T-cell e binding to HLA B18
46-EPDRAHYNIV-55
SEQ-ID 69, HPV E7 T-cell epitope binding to HLA DQ2
35-EDEIDGPAGQAEPDRA-50
SEQ-ID 70, HPV E7 T-cell epitope g to HLA DR3
43-GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR-77
SEQ-ID 71, HPV E7 T-cell epitope binding to HLA DR15
NIVTFCCKCD-62
SEQ-ID 72, HPV E7 T-cell epitope binding to HLA DR17
58-CCKCDSTLRLC-68
SEQ-ID 73, HPV E7 T-cell epitope binding to HLA-DRB1*0901
61-CDSTLRLCVQSTHVDIRTLE-80
SEQ-ID 74, PSA T-cell epitope binding to HLA-A2
146-KLQCVDLHV-154
SEQ-ID 75, PSA T-cell epitope binding to HLA-A2
141-FLTPKKLQCV-150
SEQ-ID 76, PSA T-cell epitope binding to HLA-A2
154-VISNDVCAQV-163
SEQ-ID 77, PSA T-cell epitope binding to HLA-A2
154-YISNDVCAQV-163
SEQ-ID 78, PSA T-cell epitope binding to HLA-A3
162-QVHPQKVTK-170
SEQ-ID 79, PSA T-cell epitope g to HLA-A24
152-CYASGWGSI-160
SEQ-ID 80, PSA T-cell epitope binding to HLA-A24
RKWIKDTI-257
SEQ-ID 81, PSMA T-cell epitope binding to HLA-A2
4-LLHETDSAV-12
SEQ-ID 82, PSMA T-cell epitope binding to HLA-A2
711-ALFDIESKV-719
SEQ-ID 83, PSMA T-cell epitope binding to HLA-A2
27-VLAGGFFLL-35
SEQ-ID 84, PSMA T-cell epitope binding to HLA-A24
178-NYARTEDFF-186
SEQ-ID 85, PSMA T-cell e binding to HLA-A24
227-LYSDPADYF-235
SEQ-ID 86, PSMA T-cell epitope binding to HLA-A24
624-TYSVSFDSL-632
SEQ-ID 87, PAP T-cell epitope binding to HLA-A2
DVYNGLL-307
SEQ-ID 88, PAP T-cell epitope binding to HLA-A24
213-LYCESVHNF-221
SEQ-ID 89, PAP T-cell epitope binding to MHC-2
199-GQDLFGIWSKVYDPL-213
SEQ-ID 90, PAP T-cell epitope binding to MHC-2
DTMTKLRELSELS-242
SEQ-ID 91, PSCA T-cell epitope binding to HLA-A2
PGTALL-22
SEQ-ID 92, PSCA T-cell epitope g to HLA-A2
105-AILALLPAL-113
SEQ-ID 93, PSCA T-cell epitope binding to HLA-A2
7-ALLMAGLAL-15
SEQ-ID 94, PSCA T-cell epitope binding to HLA-A2
21-LLCYSCKAQV-30
SEQ-ID 95, Kallikrein 4 T-cell epitope binding to DRB1*0404
155-LLANGRMPTVLQCVN-169
SEQ-ID 96, Kallikrein 4 T-cell epitope binding to DRB1*0701
160-RMPTVLQCVNVSVVS-174
SEQ-ID 97, Kallikrein 4 T-cell epitope binding to DPB1*0401
125-SVSESDTIRSISIAS-139
SEQ-ID 98, EBV nuclear antigen 3 T-cell epitope binding to MHC I HLA B8
FLRGRAYGL
SEQ-ID 99, HLA-A2 restricted CD8+ T-cell epitope of PAP binding to HLA-A2
FLFLLFFWL
SEQ-ID 100, HLA-A2 restricted CD8+ T-cell epitope of PAP g to HLA-A2
TLMSAMTNL
SEQ-ID 101, HLA-A2 restricted CD8+ T-cell epitope of PAP binding to HLA-A2
ALDVYNGLL
SEQ-ID 102, human .1-restricted CTL epitope of PAP-3 g to HLA A2.1
ILLWQPIPV
SEQ-ID 103, HLA-A2.1-restricted CTL epitope of 3 binding to HLA-A2.1
LLLGTIHAL
SEQ-ID 104, HLA-A2.1-restricted CTL epitope of MUC-1 and MUC-2 binding to
HLA-A2.1
CHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPA
SEQ-ID 105, single chain HLA-A0201/FLWGPRALV construct.
MAVMAPRTLVLLLSGALALTQTWAFLWGPRALVGGGGSGGGGSGGGGSGGGSGIQRTPKIQV
YSRHP
AENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYA
CRVNH
VTLSQPKIVKWDRDMGGGGSGGGGSGGGGSGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQF
VRFDSDA
ASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSESHTVQRMYGCDV
GSDWRFLRG
YHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYL
ENGKETLQRT
DSPKAHVTHHPRSKGEVTLRCWALGFYPADITLTWQLNGEELTQDMELVETRPAGDGTFQKW
ASVVVPLG
KEQNYTCRVYHEGLPEPLTLRWEPPPSTDSYMVIVAVLGVLGAMAIIGAVVAFVMKRRRNTGG
P GSQSSEMSLRDCKA
Claims (17)
1. An immunoglobulin linked with a toxic moiety, comprising at least an globulin variable region that specifically binds to an MHC-peptide 5 complex preferentially associated with aberrant cells, wherein said peptide is derived from MAGE and is a peptide that is present in more than one MAGE protein, and wherein the MHC is MHC-1, and n said immunoglobulin is an antibody, an antibody fragment or a derivative of an antibody.
2. An immunoglobulin linked with a toxic moiety according to claim 1, wherein 10 the antibody fragment is an Fab or the antibody tive is an ScFV.
3. The immunoglobulin linked with a toxic moiety according to claim 1, wherein said immunoglobulin variable region is a Vh or Vhh.
4. The immunoglobulin linked with a toxic moiety according to claim 3 wherein said immunoglobulin variable region further comprises a Vl. 15
5. The immunoglobulin linked with a toxic moiety according to claim 4 being a human IgG.
6. The immunoglobulin linked with a toxic moiety according to any one of claims 1 to 5, wherein the toxic moiety is chemically linked to the immunoglobulin.
7. The immunoglobulin linked with a toxic moiety according to any one of claims 20 1 to 6, wherein the toxic moiety is a proteinaceous toxic .
8. The immunoglobulin linked with a toxic moiety according to claim 7, wherein the immunoglobulin is linked with the proteinaceous toxic moiety by a peptide linker.
9. The immunoglobulin linked with a toxic moiety according to claim 8, wherein 25 the immunoglobulin linked to the toxic moiety is d at the DNA level.
10. A pharmaceutical ition comprising an immunoglobulin linked with a toxic moiety according to any one of claims 1 to 9 and a suitable diluent and/or ent.
11. Use of an immunoglobulin linked with a toxic moiety according to any of 30 claims 1 to 9, in the manufacture of a ment for the treatment of a host suffering from a disease associated with aberrant cells.
12. Use according to claim 11, wherein the toxic moiety is internalized into the nt cell during said treatment.
13. Use of an immunoglobulin linked with a toxic moiety according to any of claims 1 to 9, in the manufacture of a medicament, for the treatment of a host suffering from , wherein at least the toxic moiety is internalized into the aberrant cell during said treatment. 5
14. An immunoglobulin according to claim 1, ntially as herein described or exemplified.
15. A pharmaceutical composition according to claim 10, ntially as herein described or exemplified.
16. A use according to claim 11, substantially as herein described or exemplified. 10
17. A use according to claim 13, substantially as herein described or exemplified. APO-T B.V. By their Attorneys HENRY HUGHES IP 15 Per:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261586568P | 2012-01-13 | 2012-01-13 | |
US61/586,568 | 2012-01-13 | ||
NZ62730013 | 2013-01-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ724880A NZ724880A (en) | 2021-03-26 |
NZ724880B2 true NZ724880B2 (en) | 2021-06-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210205465A1 (en) | Aberrant cell-restricted immunoglobulins provided with a toxic moiety | |
CN112646031B (en) | Anti-4-1 BB nanobody and application thereof | |
US7999077B2 (en) | IRTA2 antibodies and methods of use | |
US20180071398A1 (en) | Polypeptide that binds aberrant cells and induces apoptosis | |
JP7027530B2 (en) | Antibodies to human DLK1 and their uses | |
US20180318440A1 (en) | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use | |
JP2018524296A (en) | CD123 antibody and complex thereof | |
WO2020228806A1 (en) | Antibody against claudin 18a2 and use thereof | |
AU2011353197B2 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding MHC-MAGE complex that induces apoptosis | |
CA3031559A1 (en) | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof | |
WO2016022939A1 (en) | Human monoclonal antibodies specific for 5t4 and methods of their use | |
US20230365676A1 (en) | Cd33 antibodies | |
NZ724880B2 (en) | Aberrant cell-restricted immunoglobulins provided with a toxic moiety | |
NZ724880A (en) | Aberrant cell-restricted immunoglobulins provided with a toxic moiety | |
WO2023143315A1 (en) | Ror1-targeted antibody or antigen-binding fragment thereof and use thereof | |
WO2023169328A1 (en) | Ror1-targeted binding molecule and use thereof | |
WO2023222068A1 (en) | Anti-cd200r1 antibodies | |
WO2023190465A1 (en) | Human anti-sema7a antibody |